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Abstract 
Janne O. Koskinen 
TWO-PHOTON EXCITATION FLUOROMETRY IN  
DETECTION OF INFECTIOUS DISEASES 
Laboratory of Biophysics, Institute of Biomedicine, University of Turku 
(Turun yliopisto), Finland 
Laboratory of Diagnostic Microbiology, Turku University of Applied 
Sciences (Turun ammattikorkeakoulu), Finland 
Annales Universitatis Turkuensis, Painosalama Oy, 2008 
Because of the heavily overlapping symptoms, pathogen-specific 
diagnosis and treatment of infectious diseases is difficult based on 
clinical symptoms alone. Therefore, patients are often treated 
empirically. More efficient treatment and management of infectious 
diseases would require rapid point-of-care compatible in vitro 
diagnostic methods. However, current point-of-care methods are 
unsatisfactory in performance and in cost structure. The lack of point-
of-care methods results in unnecessary use of antibiotics, suboptimal 
use of virus-specific drugs, and compromised patient care. 
In this thesis, the applicability of a two-photon excitation fluorometry 
is evaluated as a tool for rapid detection of infectious diseases. New 
separation-free immunoassay methodologies were developed and 
validated for the following application areas: general inflammation 
markers, pathogen-specific antibodies, pathogen-specific antigens, and 
antimicrobial susceptibility testing. In addition, dry-reagent 
methodology and nanoparticulate tracers are introduced in context to 
the technique. 
The results show that the new assay technique is a versatile tool for 
rapid detection of infectious diseases in many different application 
areas. One particularly attractive area is rapid multianalyte testing of 
respiratory infections, where the technique was shown to allow simple 
assay protocols and comparable performance to the state-of-the-art 
laboratory methods. If implemented in clinical diagnostic use, the new 
methods could improve diagnostic testing routines, especially in rapid 
testing of respiratory tract infections. 
Keywords: infectious diseases, nanoparticles, rapid point-of-care 




Janne O. Koskinen 
KAKSOISFOTONIVIRITTEINEN FLUORESENSSI-
TEKNIIKKA INFEKTIOTAUTIEN DIAGNOSTIIKASSA 
Biofysiikan laboratorio, Biolääketieteen laitos, Turun yliopisto 
Diagnostisen mikrobiologian laboratorio, Turun ammattikorkeakoulu 
Annales Universitatis Turkuensis, Painosalama Oy, 2008 
Eri infektiotautien aiheuttamat kliiniset oireet voivat olla hyvin 
samankaltaiset. Tästä syystä infektiotautien patogeeni-spesifinen 
diagnosointi ja hoito on vaikeaa pelkän oirekuvan perusteella. Potilaita 
joudutaan hoitamaan usein empiirisesti. Tehokkaampi infektiotautien 
hoito vaatisi parempia in vitro –pikatestejä, sillä nykyisten 
pikatestimenetelmien suorituskyky on epätyydyttävä. Potilasläheisen 
diagnostiikan ongelmat johtavat toisaalta antibioottien liikakäyttöön ja 
toisaalta virus-spesifisten lääkkeiden tehottomaan käyttöön. Näistä 
seurauksena on tingitty potilaan hoito. 
Tässä väitöskirjassa tutkittiin kaksoisfotoniviritteisen fluoresenssi -
tekniikan soveltuvuutta infektiotautien pikadiagnostiikkaan. Työssä 
kehitettiin erotusvapaat immunomääritysmetodologiat seuraaville 
sovellus-alueille: yleiset tulehdusmerkkiaineet, patogeeni-spesifiset 
vasta-aineet, patogeenien antigeeniosoitus ja antibioottiherkkyys-
määritys. Lisäksi työssä esitellään kuivattujen reagenssien ja 
nanopartikkelikoettimien käyttö uuden tekniikan yhteydessä. 
Tulosten mukaan uusi määritystekniikka on monikäyttöinen työkalu 
infektiotautien pikadiagnostiikassa. Erityisen houkutteleva sovellus-
alue olisi hengitystieinfektioiden monianalyyttinen potilasläheinen 
pikatestaus. Uutta tekniikkaa voidaan pitää merkittävänä parannuksena 
perinteisiin pikatesteihin verrattuna. Kliiniseen diagnostiseen käyttöön 
sovellettuna uudet menetelmät voisivat merkittävästi parantaa 
diagnostisia testausrutiineja. 
Avainsanat: erotusvapaa immunomääritys, infektiotaudit, kaksois-
fotoniviritteinen fluorometria, nanopartikkelit, pikadiagnostiikka 
 VII
Contents 
PREFACE  .......................................................................................................................... II 
ABSTRACT  .......................................................................................................................... V 
TIIVISTELMÄ ........................................................................................................................ VI 
CONTENTS  ....................................................................................................................... VII 
LIST OF ORIGINAL PUBLICATIONS ............................................................................... IX 
ABBREVIATIONS................................................................................................................... X 
1 INTRODUCTION ......................................................................................................... 1 
1.1 RESPIRATORY TRACT INFECTIONS ........................................................................... 2 
1.1.1 Health and Economic impact ......................................................................... 2 
1.1.2 Etiology and difficulty of diagnosis ............................................................... 4 
1.1.3 Unnecessary use of antibiotics ....................................................................... 8 
1.2 BIOAFFINITY TECHNIQUES FOR PATHOGEN DETECTION ......................................... 10 
1.2.1 Diagnostic tests ............................................................................................ 11 
1.2.2 Trends in laboratory testing ......................................................................... 17 
1.2.3 New techniques proposed for rapid point-of-care testing ............................ 19 
1.3 ANTIMICROBIAL SUSCEPTIBILITY TESTING ............................................................ 22 
1.3.1 Methods based on culture ............................................................................ 22 
1.3.2 Methods based on immunoassay ................................................................. 23 
1.3.3 Methods based on nucleic acid amplification .............................................. 24 
1.4 CLINICAL PHASE OF AN INFECTION ........................................................................ 25 
1.4.1 Systemic markers of acute infection ............................................................ 25 
1.4.2 Specific markers of infection ....................................................................... 25 
1.5 TWO-PHOTON EXCITATION ASSAY TECHNIQUE ...................................................... 28 
2 AIMS OF THE STUDY .............................................................................................. 31 
3 MATERIALS AND METHODS ................................................................................ 32 
3.1 MATERIALS ........................................................................................................... 32 
3.2 METHODS .............................................................................................................. 32 
4 RESULTS .................................................................................................................... 35 
4.1 PREPARATION AND OPTIMIZATION OF IMMUNOASSAY REAGENTS ......................... 35 
4.2 DRY-CHEMISTRY REAGENTS ................................................................................. 36 
4.3 NANOPARTICULATE TRACERS ............................................................................... 36 
4.4 ANTIGEN DETECTION OF RESPIRATORY TRACT PATHOGENS .................................. 39 
4.5 DETECTION OF SPECIFIC ANTIBODIES .................................................................... 42 
4.6 ON-LINE DETECTION OF MICROBIAL GROWTH ....................................................... 44 
4.7 ANTIMICROBIAL SUSCEPTIBILITY TESTING ............................................................ 45 
5 DISCUSSION .............................................................................................................. 46 
5.1 DRY-CHEMISTRY REAGENTS.................................................................................. 46 
5.2 MULTIANALYTE POINT-OF-CARE TESTING OF RESPIRATORY PATHOGENS .............. 48 
5.3 ANTIBODY BRIDGING − AVIDITY INDEX TECHNIQUE .............................................. 51 
5.4 ANTIMICROBIAL SUSCEPTIBILITY TESTING ............................................................ 53 
 VIII
6 CONCLUSIONS AND PROSPECTIVE ................................................................... 55 
7 BIBLIOGRAPHY ........................................................................................................ 56 
APPENDIX 1: REFERENCES FOR TABLE 1 .................................................................... 70 
APPENDIX 2: SENSITIVE NANOPARTICULATE TRACER METHOD FOR 
THYROID STIMULATING HORMONE ................................................... 71 
APPENDIX 3: CONCOMITANT ASSAY METHOD FOR INFLUENZA A AND B 
VIRUSES ......................................................................................................... 73 
ORIGINAL PUBLICATIONS ................................................................................................ 77 
 
 IX
List of original publications 
This doctoral thesis is based on the following original publications, 
which will be referred to the Roman numerals I-V. In addition, some 
unpublished data are presented. 
I. Janne O. Koskinen, Jonne Vaarno, Niko J. Meltola, Juhani T. 
Soini, Pekka E. Hänninen, Juhani Luotola, Matti E Waris, and 
Aleksi E. Soini. Fluorescent nanoparticles as labels for 
immunometric assay of C-reactive protein using two-photon 
excitation assay technology. Analytical Biochemistry (2004), 
328(2):210-218. 
II. Janne O. Koskinen, Niko J. Meltola, Erkki Soini, and Aleksi E. 
Soini. A lab-on-a-chip compatible bioaffinity assay method for 
human alpha-fetoprotein. Lab on a Chip (2005), 5(12):1408-1411. 
III. Janne O. Koskinen, Jonne Vaarno, Raija Vainionpää, Niko J. 
Meltola, and Aleksi E. Soini. A novel separation-free assay 
technique for serum antibodies using antibody bridging assay 
principle and two-photon excitation fluorometry. Journal of 
Immunological Methods (2006), 309(1-2):11-24. 
IV. Janne O. Koskinen, Raija Vainionpää, Niko J. Meltola, Jori 
Soukka, Pekka E. Hänninen, Aleksi E. Soini. Rapid method for 
detection of influenza A and B virus antigens by use of a two-
photon excitation assay technique and dry-chemistry reagents. 
Journal of Clinical Microbiolology (2007), 45(11):3581-3588.  
V. Janne O. Koskinen, Teppo Stenholm, Jonne Vaarno, Jori Soukka, 
Niko J. Meltola, and Aleksi E. Soini. Development of a rapid 
assay methodology for antimicrobial susceptibility testing of 
Staphylococcus aureus. Diagnostic Microbiology and Infectious 
Diseases, in press (2008). 
The original publications have been reproduced by permission of the 
copyright owners: 
I, III, V Elsevier, Reed Elsevier Group plc, London, UK. 
II The Royal Society of Chemistry, London, UK  
IV American Society for Microbiology, Washington, USA 
 X
Abbreviations 
AB Antibody bridging 
AI Avidity index 
AOM Acute otitis media 
AST Antimicrobial susceptibility testing 
BSA Bovine serum albumin 
CRP C-reactive protein 
EBV Epstein-Barr virus 
EDAC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 
ELISA Enzyme linked immunosorbent assay 
HIV Human immunodeficiency virus 
HNL Human neutrophil lipocalin 
hTSH Human thyroid stimulating hormone 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
MES 2-(N-morpholino)ethanosulfonic acid 
mM Millimolar (concentration) 
MRSA Methicillin resistant Staphylococcus aureus 
MT Molecular tracer 
NAA Nucleic acid amplification 
nM Nanomolar (concentration) 
NPT Nanoparticulate tracer 
OECD Organisation for economic co-operation and 
development 
PCR Polymerase chain reaction 
pM Picomolar (concentration) 
POC Point-of-care 
RSV Respiratory syncytial virus 
RTI Respiratory tract infection 
TPX Bioaffinity assay technique based on two-photon 
excited fluorescence  
TR-FIA Time-resolved fluoroimmunoassay 
URTI Upper respiratory tract infection 




Infectious diseases are, along with cardiovascular diseases, a leading 
cause of death worldwide. Infectious diseases are estimated to be 
directly related to more than 25 % (15 million) of annual deaths, while 
respiratory tract infections (RTI) alone cause 7 % (4 million) and HIV 
(human immunodeficiency virus) 5 % of all deaths (WHO 2004). The 
percentages of different causes of death vary significantly between 
developed and developing countries (Guerrant 1999, WHO 2004, 
Lopez 2006), as well as by social status (Butler 2001). However, lower 
respiratory tract infections are a significant cause of death in all 
countries regardless of the average income level (Lopez 2006). The 
fact that infectious diseases often cause life-long disability and 
premature death at an early age increases their impact (Fauci 2001, 
WHO 2004, Lopez 2006). A significant percentage of the deaths and 
disabilities (a few million annual deaths) could be avoided by 
vaccination (GAVI Alliance 2004). Interestingly, the estimated number 
of infection-attributable cancers in the year 2002 was two million 
cases, 18 % of the global cancer burden (Parkin 2006). 
The terms emerging and re-emerging infectious diseases are frequently 
used to describe infectious diseases. The emerging include new 
pathogens such as acquired immunodeficiency syndrome (AIDS) and 
severe acute respiratory syndrome (Peiris 2003). The re-emerging 
include old diseases such as malaria (Wellems 2003), tuberculosis 
(Espinal 2003), influenza A (avian influenzas, Olsen 2006), and drug-
resistant microbes (WHO 2005). Many public health experts believe 
that the emergence of a new influenza pandemic is only a matter of 
time, and that it will occur during this century (Fauci 2001). 
The threats that infectious diseases pose to public health today have 
been realized by the health care authorities and by the specialist (Fauci 
2001, WHO 2004, Morens 2004) as well as by the general public. 
Infectious diseases are among the most significant threats (along with 
oil, water, and food) that endanger economic development and political 
stability. Therefore, massive resources will be directed to infectious 
diseases research; to the development of new vaccines, antimicrobial 
drugs, and diagnostics. (Fauci 2001, OECD 2003) In contrast to many 
other market fields of laboratory testing, infectious diseases testing is 
not highly saturated and the market potential is high. 
Management of infectious diseases is complicated by the overlapping 
symptoms and the lack of efficient point-of-care diagnostic methods 
(Perkins 2006). From the physician’s point of view, efficient testing 
Introduction 
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would help to treat patients according to the cause of the symptoms 
(etiology) in contrast to empirical treatment. From the patient’s point 
of view, the benefits are in minimizing human suffering and saving 
life. On a more general level, testing for infectious diseases allows 
epidemiological follow up, aids in directing resources, and improves 
public health. 
The literature review of this thesis is focused on aspects related to in 
vitro diagnostic testing of infectious diseases present in every day 
clinical practice. In particular, the review aims to pinpoint common 
bottlenecks in the diagnostic practice, and to evaluate what kind of 
diagnostic tools would be needed to resolve these. RTIs are given most 
weight due to their frequency and economic impact.  
1.1 Respiratory tract infections 
Diagnosis of patients with RTI symptoms is usually based on clinical 
findings and anamnesis, while less frequently diagnosis is confirmed 
by laboratory analysis. Unfortunately, symptoms and clinical findings 
of different pathogens are variable and heavily overlap, even between 
viral and bacterial infections (Perkins 2006). Therefore, it is difficult to 
obtain a reliable etiological diagnosis in RTIs based on the clinical 
picture alone. Hence, usually the diagnosis is more descriptive of the 
symptoms (syndrome) than the causative agent. Rapid pathogen 
detection tests are available for several pathogens but their use is 
limited for several reasons. Tests for general inflammation markers 
such as C-reactive protein (CRP) are done more often to help in 
differential diagnosis, although the results have poor correlation with 
the etiological diagnosis. 
1.1.1 Health and Economic impact 
Respiratory tract infections are among the most common infectious 
diseases. On average, children suffer from up to dozen and adults from 
a few RTIs annually. RTIs cause 25 % of all infectious diseases deaths 
(WHO 2004), and their severity is pronounced in children, the elderly, 
the chronically ill, and in areas of low hygiene and poor nutrition. 
Globally, two million children die annually from acute RTIs, 
accounting for 10 to 20 % of all childhood deaths (Williams 2002). 
Influenza and respiratory syncytial viruses markedly increase mortality 
in infants and in the elderly. Generally, respiratory syncytial virus 
(RSV) is more severe in infants, whereas influenza is more severe in 
elderly people. (Willams 2002, Thompson 2003) The viruses are 
responsible for most of the RTI deaths in the developed countries 
Introduction 
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(Thompson 2003, Fleming 2005). Mortality is not usually a direct 
consequence of influenza or RSV infection but a result of 
complications, such as bacterial pneumonia (Beadling 2004).  
Virus infections seem to predispose to secondary bacterial infections 
which may lead to lethal synergism (Beadling 2004). Because of this, 
the health of the most vulnerable should be monitored carefully if they 
are found to be positive for viruses. Importantly, treatments that 
diminish the magnitude of initial viral infection seem to protect from 
subsequent bacterial infection (Linde 2001, Beadling 2004, Peltola 
2005a). 
In Finland, adults have 0.5 RTI-related medical consultations per 
annum (Pirhonen 1994), and 40 % of persons having RTI seek medical 
attention (Aromaa 2002). RTIs are responsible for 25 % of outpatient 
doctor visits and 40 % of sick leaves in Finland (Jussila 2005). RTIs 
constitute more than three quarters of all infections, the most common 
diagnoses being common cold, acute otitis media (AOM), throat 
infection, and sinusitis (Rautakorpi 2006a). Similar statistics were 
found in the USA where every person had, on average, 0.8 respiratory 
infections per year. Patients with influenza, common cold, other acute 
upper respiratory tract infection (URTI), acute bronchitis, pneumonia, 
and acute ear infections sought medical attention in 36 %, 43 %, 87 %, 
90 %, 91 %, and 99 % of cases, respectively. (Adams 1999) 
The economic impact of all RTIs is significant. Most of the costs are 
due to sick leave and medical consultations, while medication is 
responsible for only some ten per cent (Birnbaum 2002, Fendrick 
2003, Jussila 2005). Many of the consultations are unnecessary in 
terms of recovery and treatment. In the USA, 25 million people visit 
their family doctors because of uncomplicated RTI (Gonzales 2001). 
The common cold alone accounts for 20 million out-of-work days and 
a similar number of absent days from school annually (Adams 1999). 
A substantial number of out-of-work days of the parents are a result of 
their child’s disease (Heikkinen 2004). The annual costs of viral RTIs 
in the USA have been estimated to amount to $40 billion (Fendrick 
2003). Extrapolation to Finland gives costs amounting to €1 000 
million. 
Birnbaum et al. (2002) analysed the economic burden of RTIs in the 
USA from the employer perspective. Annual per capita employer 
expenditures totalled $4 400 and the overall costs, including treatment 
costs and time lost from work, were around $110 billion in 1997. The 
figures do not include indirect costs due to workforce distribution. The 
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huge health and economic impact of RTIs suggests that significant cost 
savings could be achieved with more efficient disease management. 
1.1.2 Etiology and difficulty of diagnosis  
Etiology of RTIs is extremely diverse. Symptoms are sometimes 
atypical, heavily overlap, and differ from patient to patient. Knowing 
the epidemiological status helps the clinician in making diagnoses. 
Still, pathogen-specific diagnosis is virtually impossible on clinical 
grounds alone. Table 1 presents a summary of the most common 
causative agents of RTIs. 
Rhinoviruses are responsible for up to half of all common cold cases 
(Mäkelä 1998, Pitkäranta 1998, Monto 2002 and 2004), while rapid 
diagnostic testing of rhinoviruses is complicated by the high number of 
serotypes (Heikkinen 2003a). This makes development of an 
immunoassay challenging; despite the high incidence and clinical 
significance of the virus, immunoassay tests are not commercially 
available. Rhinoviruses have also been associated with lower RTIs 
(Juven 2000, Savolainen 2003). The common cold is sometimes 
difficult to differentiate from bacterial infections (Puhakka 1998b, 
Heikkinen 2003a). However, only a small proportion of common colds 
are complicated by bacterial infections (Mäkelä 1998). Antibiotic 
treatment of patients with bacterial indication might shorten the 
duration of the symptoms, but prescription would require in vitro 
evidence of bacteria (Kaiser 1996). 
Pharyngitis and tonsillitis cases are mostly (40 %) caused by viruses, 
especially in children under 3 years (Putto 1987). The most common 
etiological viruses are adenoviruses (20 %) and EBV (10 %) (Putto 
1987). Bacterial pharyngitis is most common in children over 6 years. 
The clinical findings of group A streptococcal and viral pharyngitis 
broadly overlap, and accurate diagnosis by clinical signs alone is 
difficult. Streptococcus A is the most common bacterial etiological 
agent of acute pharyngitis. Still it causes only 5−10 % and 15−30 % of 
the total pharyngitis cases in adults and in older pediatric patients, 
respectively (Bisno 2002).  
Introduction 
 5
Table 1. Causative agents of common respiratory tract infections (see 
Appendix 1 for reference information) 
Diagnosis 
(syndrome) Etiology (pathogen found) Reference
Common cold Rhinoviruses 50 % 9, 18
Coronaviruses 5−15 % 5, 18
Influenza viruses 5−30 % 5, 18
Parainfluenza viruses 5 % 5, 18
Adenovirus less than 5 % 5, 18
Metapneumovirus 2−5 % 11, 14
Bacterial 5−10 % 2, 10
Throat infection Bacterial 20−40 % 2, 6
Streptococcus pyogenes  15−30 % in youths, 
5−10 % in adults 6
Adenovirus 20 % 6
Epstein-Barr virus 10 % 6
All viruses together 40 % in children 6
Unknown 30 % 6
Acute otitis Bacterial 65−80 % 2, 5, 16
media Streptococcus pneumoniae 25−50 % 16, 17
Haemofilus influenzae 15−50 % 16, 17
Moraxella catarrhalis 2−55 % 16, 17
Sole viral 1-5 %, virus found in 20−70 % 5, 16, 17
Co-infection of bacterium and virus 60−70 % 7, 8, 17
Unknown less than 25 % 5, 17
Acute bronchitis Viruses (influenza and others) 80−90 %
Bacterial 10 % 2
Pneumonia Streptococcus pneumoniae 40 % in children 
(sole agent in 15 %), 20−30 % in adults 1, 4, 15
Haemofilus influenzae 10 % in viral co-
infections in children, 4 % in adults 1, 4
Mycoplasma pneumoniae  5 % in children, 10  
% in adults 1, 4
Chlamydia pneumonia 3 % in children, 7 % in 
adults 1, 4
Sole viral in children 30 %, virus found in 
children 60 %, sole viral in adults 10−30 % 1, 4, 12, 15
Co-infection of bacterium and virus 30 % in 
children, 10−30 % in adults 1, 3, 12, 15
Acute Sinusitis Bacterial 20−40 % 2, 10, 12
Streptococcus pneumoniae 20−35 %
Haemofilus influenzae 5−25 %
Moraxella catarhalis 2−10 % 10
Viruses 80 % in context of common cold 13  
Introduction 
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Acute bronchitis is usually caused by influenza, parainfluenza, RS-, or 
metapneumovirus (Hamelin 2005). However, chronic viral bronchitis 
can predispose to bacterial infection. Symptoms and causative agents 
closely resemble those of common cold and pneumonia. The 
differentiation between bronchitis (antibiotic treatment not 
recommended) and pneumonia (antibiotic treatment recommended) is 
difficult based on clinical findings. For instance, the positive predictive 
value, sensitivity, and specificity of clinical signs for influenza are 
very low, ranging from 20 % to 80 % at optimum conditions (Carrat 
1999, Monto 2000, Peltola 2005b). 
In bronchiolitis, RSV is the most prominent etiological agent in small 
children. Acute wheezing is caused by RSV or picornaviruses in three 
out of four cases (Jartti 2004, Lehtinen 2007). 
In pneumonia, the diagnostic problem is the same as in bronchitis. 
Clinical signs are not sensitive and specific enough for differential 
diagnosis. Rapid tests that would give reliable information about the 
etiology are not available (File 2003). In adults, the etiological agent is 
usually bacterial but also viruses are a common cause (Angeles Marcos 
2006, Hohenthal 2008). Bacterial pneumonia is most often caused by 
S. pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, or 
Haemophilus influenzae. The etiological agent in children is usually 
viral but also co-infections with bacteria are found (Table 1) 
(Heiskanen-Kosma 1998, Juven 2000). During the first years of life, 
RSV, rhinoviruses, and S. pneumoniae are involved in the majority of 
child pneumonias (Juven 2000), while also metapneumovirus is found 
in older children (Hamelin 2005). Viral lower RTIs in children are 
often associated with bacterial upper RTIs, whereas co-existence with 
bacterial lower RTI is rare (10-20 %) (Lehtinen 2006). Development of 
bacterial pneumonia is found even less often (in a few percent of cases, 
Lehtinen 2006). According to this, a positive virus test result can be 
used to exclude bacterial complications with high probability. 
Moreover, it has been demonstrated that treatments that diminish the 
magnitude of initial viral infection help to protect from subsequent 
bacterial infection (Linde 2001, Beadling 2004, Peltola 2005a). This 
supports the need for effective virus drugs and rapid virus testing 
methods (Angeles Marcos 2006). 
In acute otitis media, respiratory viruses can be detected in 50−70 % of 
the patients. The most common findings are rhino, entero, 
metapneumo, and RS-viruses (Arola 1990, Heikkinen 1999, Ruohola 
2006, Heikkinen 2008) and they are major risk factors for AOM. The 
viruses seem to have an etiological role since they are often found in 
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the nasopharynx and in the middle ear fluid (Arola 1990, Heikkinen 
1999, Heikkinen 2003b, Lehtinen 2006). Pathogenic bacteria are found 
in the middle ear fluid in 9 out of 10 cases (Heikkinen 1999, Ruohola 
2006), but often also in the nasopharynx (Arola 1990). In 60−70 % of 
patients both bacteria and viruses are found (Heikkinen 2003b, 
Ruohola 2006), and they are thought to evoke a synergistic effect 
(Heikkinen 2003b). 
Sinusitis and AOM caused by a virus may be accompanied with 
bacterial infection. The diagnostic problem is how to identify those 
who would recover well without an antibiotic from those who would 
benefit from it. Early treatment of influenza with virus-specific drug 
has been shown to reduce the development of AOM by more than 40 
% (Whitley 2001). The few days time window between viral infection 
and the onset of AOM allows the opportunity for intervention, 
provided that rapid diagnostic methods are available (Heikkinen 
2003b).  
Approximately half of bacterial sepsis cases are preceded by acute 
RTIs (Beadling 2004, Peltola 2006a). Outbreaks of respiratory viral 
infections, especially RSV and influenza viruses, are associated with 
an increased incidence and/or severity of bacterial co-infections. The 
clinical symptoms associated with co-infections are more severe and 
last for a longer time compared to the respective viral or bacterial 
single infections. In co-infections, non-dangerous infections may 
become fatal. For effective and correct therapy, the causative agent 
should be determined. Monitoring of the pathogen repertoire of the 
patient would also help to predict the probability of sepsis. In some 
cases the antimicrobial response of the infectious agent should also be 
studied. (Beadling 2004, Angeles Marcos 2006) 
So far, influenza is the only RTI virus disease for which specific anti-
viral drugs are available. At present, the use of these drugs is still 
relatively uncommon. The situation may be considered unethical as 
influenza is a severe disease for which an effective medication exists 
(Personal communication, Docent Terho Heikkinen, May 16th 2008, 
ESPID, Graz, Austria). The lack of drugs for the other viruses has been 
used as an argument against wide testing of virus RTIs. Currently, 
specific drugs for RSV are in the pipeline (Datamonitor 2006). 
Nonetheless, testing of the other viruses is clinically useful, for 
example, as an exclusionary factor, in disease monitoring, and in 
reducing the use of antibiotics. Moreover, early identification of acute 
RTIs might enable the lowering of crib deaths (Samuels 2003). The 
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development of new methodologies for RTI pathogen testing, along 
with the development of anti-viral drugs, would be important. 
1.1.3 Unnecessary use of antibiotics 
Eighty per cent (80 %) of the total antibiotic burden is determined by 
outpatient use, with most antibiotics being prescribed for RTIs (Wise 
1998). A significant fraction (up to 60−70 %) of the antibiotic use is 
questionable if not totally unnecessary (Wise 1998). In acute RTIs in 
the USA this fraction is about 55 % (Gonzales 2001). Most of the 
unnecessary antibiotics are used to treat bronchitis and pharyngitis, 
although both of the diseases are most often caused by viruses. No 
scientific evidence exists to support high antibiotic prescription rates in 
bronchitis (60−85 % of patients, Gonzales 1997, Rautakorpi 2006b) 
and in pharyngitis (60−95 % of patients, Nyquist 1998, Bisno 2002, 
Rubin 2005). 
Most of the patients with acute cough (Fahey 1998), common cold 
(Mäkelä 1998), AOM (Glasziou 2004) or viral sinusitis (Puhakka 
1998b) do not benefit from antibiotic treatment. Yet, most patients 
(80−95 %) with AOM and sinusitis are currently prescribed with 
antibiotics in Finland (Rautakorpi 2006b). The common cold, on the 
other hand, is less often treated with antibiotics in Finland (Rautakorpi 
2006b). In the USA, the use of antibiotics for common colds is 
markedly higher; up to 50 % (Gonzales 1997, Nyquist 1998, Rubin 
2005). When bacterial complications are considered probable, or the 
consequences of a secondary bacterial infection are severe, the use of 
antibiotics may still be justified (Beadling 2004). 
Antibiotic treatment of acute bronchitis has little or no effect on the 
course of the illness (Orr 1993, Fahey 1998, Fahey 2004). Thus, it is 
not recommended for otherwise healthy patients unless there is 
evidence of bacterial etiology (WHO 2001). However, patients at risk 
of or having pneumonia should be distinguished. Even the concept of 
acute bronchitis is ambiguous since it is sometimes used as an excuse 
to justify the prescription of antibiotics. This has led to over-diagnosis 
of bronchitis (Gonzales 1998, Hueston 2000). A conservative estimate 
suggests that one third of patients with acute bronchitis or unspecified 
URTI could avoid antibiotic treatment with accurate and rapid in vitro 
diagnostic testing (Rautakorpi 2006b). 
In pharyngitis, the patient group receiving antibiotics is significantly 
higher compared to patients actually having bacterial disease (Bisno 
2002). Since S. pyogenes can not be reliably diagnosed based on 
clinical findings, an in vitro diagnostic test is required. This is usually 
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done with rapid strip tests. Due to the poor sensitivity of the tests 
(clinical sensitivity 80−90 %), negative test results need to be 
confirmed with more sensitive methods like culture (Gerber 2004). 
Sometimes patients are prescribed with antibiotics, despite the negative 
rapid test result. If the following laboratory result turns out negative, 
the therapy should be discontinued. Even this short antibiotic regimen 
and the use of back-up culturing could often be avoided if a reliable 
and sensitive rapid test method were available at the point-of-care. 
According to new guidelines, a negative rapid test result is accepted 
for exclusion of acute streptococcal pharyngitis, provided that the rapid 
test has comparable sensitivity to culture. (Bisno 2002) Indeed, 
implementation of high sensitivity rapid tests has been shown to 
improve therapeutic accuracy and patient outcome (Needham 1998). 
Positive adenovirus antigen detection test results strongly indicate non-
group A streptococcal etiology (Putto 1987). 
S. pneumoniae which is the most common pathogen in pneumonia and 
in AOM, is also found in healthy individuals. These individuals act as 
carriers of the bacteria, and this leads to low positive predictive values 
in in vitro diagnostic tests. However, negative bacterial test results 
from the nasopharynx and oropharynx have very high (90−100 %) 
negative predictive values in AOM (Eldan 2000, Syrjänen 2006) and in 
pneumonia (Boersma 1993b), respectively. Bacterial count (Syrjänen 
2006) and detection of pneumococcal antigen (Boersma 1993a) 
correlate with the disease etiology. These observations enable the use 
of such tests, especially if they provide quantitative results, in 
excluding S. pneumoniae etiology and reducing the use of antibiotics. 
Because broad spectrum antibiotics cause long-term changes in the 
composition of normal microbial flora of a patient, antibiotic treatment 
may predispose to new infections by colonization of pathogenic yeasts 
or drug-resistant microbial strains (Sullivan 2001). A fairly common 
direct side effect is diarrhoea (Beaugerie 2004), but antibiotic uptake 
may also predispose to cancer (Velicer 2004). General awareness of 
the nature of efficasy of antibiotics and about the drawbacks of 
antibiotics is growing. In the past, patients primarily sought antibiotic 
medication for RTIs, whereas currently, increasing numbers of patients 
are also interested in the cause of the illness (Butler 1998, Rautakorpi 
2006b, Global Industry Analysts). 
A rough estimate (based on the data by Gonzalez et al. 2001 and 
Ferech et al. 2006) suggests that, in Finland, annual savings of about 
ten million euro could be reached if antibiotic uptake were reduced by 
one third (estimated fraction of unnecessary courses). The savings 
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would cover the costs of significant numbers of rapid tests which could 
be done to obtain more accurate pathogen-specific diagnoses. 
However, more optimal rapid tests are needed to realize this reasoning. 
The superfluous use of antibiotics has led to the emergence of bacterial 
strains which are resistant to the antibiotics (Steinke 2001, Goossens 
2005). The spread of the resistant strains in the population is 
recognized as a major threat to public health (WHO 2000, Wise 1998). 
Increasing antibiotic resistance is often seen and felt as a community 
issue, whereas the general practitioners are mainly interested in the 
recovery of the individual patient (Butler 1998). The strategy of 
developing new antibiotic drugs has become rather inefficient and 
expensive, and therefore resources must be redirected to alternative 
disease management strategies. The formation of new resistant strains 
could be essentially slowed down by applying a more strict antibiotic 
administration policy (Rautakorpi 2006b, Peleg 2006). Strategies to 
reduce the unnecessary use have included promotion of public 
discussion and education of physicians, while success has varied from 
moderate to satisfactory (Rubin 2005, Peleg 2006). Better results could 
be achieved if the antibiotic prescription were directed by hard 
evidence, i.e. rapid identification of the pathogen and/or rapid in vitro 
susceptibility testing (Gonzales 2001).  
1.2 Bioaffinity techniques for pathogen detection 
The laboratory bioaffinity techniques most often used for detection of 
infectious diseases include enzyme linked immunosorbent assay 
(ELISA), chemiluminescence, electrochemiluminescence, time-
resolved fluorescence, flow cytometry in its various modifications, 
immunofluorescence, turbidimetry, nephelopmetry and fluorescence 
polarization. The detection techniques are implemented in various 
instrumental settings including fluorescence microscopes, plate 
readers, plate readers with automatic dispensing units, and single well 
readers capable of random-access operation. Rapid point-of-care 
techniques include lateral flow and agglutination. 
Current detection techniques fulfil the needs of a modern centralized 
clinical laboratory, whereas the most urgent need for new techniques 
lies in point-of-care (POC) testing. The use of the terms POC testing, 
decentralized testing, and near-patient testing in the literature is 
ambiguous. In this thesis, the term POC testing is used to denote 
testing that is carried out in a decentralized mode, regardless of 
whether the analysis is carried out next to the patient or in a laboratory 
of the same health care unit. 
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1.2.1 Diagnostic tests 
The need for new efficient tools for POC testing of influenza and other 
infectious diseases has recently been emphasized by the National 
Institute of Health (www.nih.gov), the Organisation for Economic Co-
operation and Development (OECD 2003), and the European 
Commission (http://cordis.europa.eu/fp7/home_en.html). Still, even 
the current methods are often notably underused in RTIs (Honkanen 
2002). This contradiction reflects the unsatisfactory performance and 
usefulness of the current methods. New diagnostic methods are needed 
both to allow immediate and correct patient care, and to allow 
epidemiological surveillance (Linde 2001, OECD 2003, Peiris 2003, 
WHO 2005). In the case of a pandemic RTI outbreak, the upper limit 
of current laboratory capacity would be rapidly reached (Linde 2001). 
This halts both the diagnostic testing and the operation of the clinics as 
huge amounts of resources are bound to exclude patients with non-
pandemic infections or psychological symptoms. In practice, specific 
diagnostic testing could currently be done only in the beginning of the 
epidemic. The threats warrant revision of the current testing capacity 
and capability. 
Testing of RTIs is mostly carried out in centralized laboratories, which 
may lead to a long result turn-around-time. For efficient disease 
management, however, the results should be available within a few 
hours’ time scale. Most preferably, the result should be available 
during the same patient visit. This warrants rapid POC methods. To 
ensure correct medication and palliative treatment, the pathogen should 
be recognized to a species level. From the test developer’s and 
manufacturer’s perspective, lack of access to clinical samples is often 
seen as a major limitation and risk for the test development (Perkins 
2006). 
Ideally, a test method should use specimens which are easy and 
painless to collect. The easiest specimen type can not always be 
applied as different pathogens replicate and accumulate in different 
locations of the respiratory tract. Nasopharyngeal aspirate is 
considered the most reliable sample type, but general practitioners 
regard sample collection cumbersome and painful, and consider it a 
major obstacle to carrying out pathogen detection (Linde 2001, Ipp 
2002, Macfarlane 2005). Nasopharyngeal and nasal swabs have been 
studied as alternatives to aspirates. Aspirate samples are somewhat 
more sensitive compared to swab samples (Covalciuc 1999, Ipp 2002, 
Heikkinen 2001, Heikkinen 2002), while the difference is rather small 
when appropriate swab material and collection procedures are used. It 
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seems that swab samples could be used for all the commonly tested 
viruses, RSV being the most problematic (Heikkinen 2002, Waris 
2007). These studies also encourage the use of nasal swabs, as the use 
of nasopharyngeal swabs is comparable to aspirate in discomfort 
(Ahluwalia 1987). 
1.2.1.1 Differential diagnosis of viruses and bacteria 
The main question in the treatment of RTIs is whether the infection is 
treatable with antibiotics or not. A simple and rapid test that would 
differentiate between bacterial and viral etiology (differential 
diagnosis) would be very useful. Several markers have been introduced 
for this purpose, such as C-reactive protein (CRP), procalcitonin, 
human neutrophil lipocalin (HNL), erythrocyte sedimentation rate, and 
white blood cell count. It is worth noting that any in vitro indication of 
viral etiology is often enough to discourage physicians from 
prescribing antibiotics. 
The problem with the general systemic inflammation markers is that 
their levels depend on several factors such as the pathogen, patient, and 
infection phase. Certain levels can only depict the probability of 
bacterial or viral disease. Accordingly, sensitivity and specificity of the 
method is always a compromise between the two. Moreover, many 
RTIs are not systemic in nature. 
Low CRP concentrations are regarded as justifying viral diagnosis, 
while high levels are used to justify a bacterial diagnosis. Recent 
results, however, show that CRP concentrations in bacterial and in 
viral infections heavily overlap (Hopstaken 2005, van der Meer 2005) 
and that results are often misinterpreted (Andre 2004). Overlapping is 
seen especially with adenoviruses (Peltola 2006b), in viral wheezing 
(Lehtinen 2006), and in pneumonia (Angeles Marcos 2006, Flood 
2008). Thus, the sensitivity and specificity of CRP (the discriminatory 
power) can be as low as 50−60 % (Flood 2008). 
Procalcitonin seems to differentiate viral and bacterial infections better 
than CRP, at least in certain systemic infections, like in bacterial 
pneumonia (Simon 2004). Another marker suggested for differential 
diagnosis is human neutrophil lipocalin (HNL). HNL is slightly better 
than CRP, but HNL concentrations still heavily overlap in bacterial 
and in viral infections (Xu 1995, Fjaertoft 2005). 
All the markers lack sensitivity and specificity compared to pathogen 
detection methods. A combination of several markers into a diagnostic 
algorithm has also been studied, to increase the sensitivity and 
specificity of differential diagnosis. Still, no combination of clinical 
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signs and markers (CRP, HNL, erythrocyte sedimentation rate, and 
white blood cell count) was found to reliably differentiate between 
bacterial and viral acute lower RTIs (Nohynek 1995, Korppi 2004). 
More recently, the expression of complement receptors on neutrophils 
has been shown to correlate with bacterial and viral etiologies, but a 
combination with several other laboratory test results is needed to 
obtain a high accuracy (Nuutila 2007). Moreover, the current 
instrumentation used for complement receptor testing (Nuutila 2006) is 
hardly implementable for POC testing. 
1.2.1.2 Specific laboratory techniques 
Diagnostic testing of infectious diseases is usually characterized by 
low frequency of positive test results. The most common bacterial 
etiological agent of acute pharyngitis, S. pyogenes, causes only 5−30 
% of the total pharyngitis cases (Bisno 2002). In the USA, only 12 and 
16 % of the tested samples (with clinical suspicions) were positive for 
influenza viruses and RSV, respectively (Thompson 2003). Common 
flu viruses can sometimes be found more often (30−50 %), but virus-
specific drugs or rapid POC tests are not available for these viruses. As 
a result, current single analyte rapid tests need to be ordered and 
evaluated with care in order to obtain clinically meaningful 
information at a reasonable cost (Linde 2001). 
In recent years, testing for RTI etiology has become more important, 
useful and cost-effective. The main reasons being the development of 
virus-specific drugs (Gubareva 2000), and the increasing opposition to 
the loose antimicrobial administration policy. Other reasons for 
carrying out pathogen testing are, for instance, 
i) epidemiology 
ii) identification of pathogen-specific clinical pictures 
iii) shortening treatment and hospitalization times 
iv) differential diagnostics 
v) treatment design 
vi) infection control, and 
vii) avoiding unnecessary examinations. 
It is also expected that the increasing general consciousness about the 
availability of virus drugs and about the shortcomings of antibiotics 
will affect the testing routines. In the future, physicians may refuse to 
prescribe antibiotics without in vitro evidence of bacteria. (Global 
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Industry Analysts) This will increase the use of and the demand for 
rapid tests. 
Techniques that have been used for laboratory testing of RTIs include 
culture, serology, antigen detection, and nucleic acid based techniques. 
Conventional culture has strengths such as its broad spectrum, but also 
drawbacks such as price and long turn-around-time. The sensitivity of 
culture methods is sometimes lower compared to other methods. In 
addition, isolated viruses often need to be identified with antibody 
reagents.  
Antigen detection 
The most important property of viral antigen detection is specificity. In 
general, virus pathogen detection has clinical specificity close to 100 
%. A false negative viral test result seldom leads to fatal consequences 
in RTIs. A false positive viral test result, in contrast, can lead to 
complications by another, undetected, disease-causing microorganism 
(Linde 2001). Results of bacterial antigen detection methods are 
sometimes complicated by healthy colonized carriers. Still, the 
bacterial antigen detection methods should have high sensitivity in 
order to avoid bacterial infections going untreated. Viruses can also be 
found from healthy carriers (van Gageldonk-Lafeber 2005), but 
healthy subjects are not tested in clinical practice. Hence, they do not 
pose a diagnostic problem if the testing coverage for other pathogens is 
sufficient. 
Most of the rapid antigen detection methods have so far relied on the 
use of lateral flow or agglutination techniques. The tests are in routine 
use even in central hospitals, although facilities for culture or ELISA 
tests are also available nearby. Technically, lateral flow and 
agglutination tests can be brought to the market quickly for a moderate 
investment, and they can be used in a broad range of applications 
(O’Farrell June 2006, Yager 2006). Development and production costs 
markedly increase when high performance is needed. Most of the 
market niches are saturated by a few large companies (Global Industry 
Analysts).  
In general, current rapid test methods are usually specific (over 95 %), 
but suffer from low sensitivity (80−90 %, Andreotti 2003, Linde 2001, 
Wild 2005, WHO 2005, Datamonitor 2006, Madeley 2007). Another 
major limitation of the current rapid tests is that they detect only one or 
two pathogens at a time (Madeley 2007). Neither of the techniques 
allows efficient testing of several analytes per patient or sample 
(multianalyte testing) (Yager 2006). Accordingly, reliable diagnosis 
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can be made only on the basis of a positive test result (Bisno 2002, 
Madeley 2007). Therefore, the current techniques are not well suited 
for RTIs where the positive sample rate is low. 
Current rapid tests are characterised by long hands-on-times which 
means high overall cost per test. Moreover, most of the tests do not 
allow easy connections to external quality control or laboratory 
information management systems. The tests usually rely on detection 
by the human eye and are thus qualitative or semi-quantitative in 
nature. Such tests are prone to readout errors. These errors can be 
reduced with automated result read-out, and an increasing number of 
automated rapid test readers are available (O’Farrel July 2006, e.g. 
www.reagena.fi). Also the label (O’Farrel July 2006) and membrane 
(O’Farrel June 2006) technologies of lateral flow tests have been paid 
attention to in pursuit of higher sensitivity and precision.  
Immunofluorescence is a common technique used for identification of 
respiratory viruses in hospital settings. The strengths of the technique 
include suitability for multianalyte detection and inherent quality 
control of sample withdrawal. However, the method is rather labour 
intensive, it takes several hours to complete, and the analysis requires 
high level of expertise. Therefore, it is not well suited to POC testing 
in primary care. In addition, its sensitivity seems to be somewhat lower 
compared to coated-tube techniques (Ahluwalia 1987, Juven 2000). 
Immunometric assay principle and detection based on coated-tube 
techniques (like ELISA and time-resolved fluoroimmunoassay, TR-
FIA), or flow-cytometry have the advantage of being sensitive, as well 
as having automated and quantitative results read-out. They also allow 
rational multianalyte testing. However, these techniques are too 
complicated and slow for POC testing (OECD 2003). Despite fairly 
short turn-around-times (1−3 hours), the sending and handling of the 
specimens lengthens the total assay times so that a result reported on 
the same day can be considered an achievement (Linde 2001).  
Nucleic acid amplification 
Nucleic acid amplification (NAA) techniques like polymerase chain 
reaction (PCR) are in principle very sensitive and specific. In clinical 
use, however, their reliability is often compromised. Polymerase 
inhibitors are frequently present in sample or swab material and they 
can lead to false negative results. Because of the inhibitors, detailed 
quality control procedures and internal controls are needed in clinical 
use. (Ieven 1997, Niesters 2004, Vernet 2004, Yang 2004) For this 
reason, and also to increase sensitivity, nucleic acid extraction is 
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usually needed. Extraction is the major bottleneck in the 
implementation of these techniques for routine cost-effective and rapid 
diagnostics (Niesters 2004, Vernet 2004). On the other hand, NAA 
methods are prone to contamination, which leads to false positive 
results. 
To construct a NAA method, the target genetic sequence has to be well 
known. This requires a lot of basic research. In addition, changes in 
genetic sequence take place more often than changes in the 
corresponding amino acid sequence. Hence, NAA methods can give 
false negative results because of new mutations, or because sample or 
amplification processing has failed (Vernet 2004). 
NAA methods can give false positive viral test results because 
sometimes genomic material is detected from the patient long after 
recovery from symptoms (Johnston 1993, Nokso-Koivisto 2002, 
Allander 2008). Also latent infections can give clinically false positive 
results as is the case for cytomegalovirus. 
Due to the complexity of NAA methods, reactions have to be carefully 
optimized with respect to all reaction parameters for every microbe 
strain (Vernet 2004, Yang 2004)). When clinical samples are analysed, 
more than one pathogen-specific probe sequence is usually required for 
a reliable diagnosis (Roth 2004). Multiplexed NAA methods have been 
developed to simplify the test protocols but multiplexing is known to 
be complicated. It also tends to decrease sensitivity and specificity. 
(Ieven 1997, Vernet 2004) Automated NAA methods have been 
developed to shorten the hands-on-times. This, however, leads to 
complicated instrumentation and reagent cartridges, and further 
increases the costs. 
In the detection of analytes for which sensitive immunoassay methods 
exist, NAA techniques can give little added value in terms of 
sensitivity or rapidity. For some pathogens, NAA methods provide a 
superior performance due to the insensitiveness of the classical 
methods for these particular pathogens. (Ieven 1997) 
Despite the limitations, several multianalyte or multiplexed assay 
systems for up to 20 respiratory tract pathogens have recently been 
introduced (e.g. www.viracor.com, www.lab-21.com). However, turn-
around-times are still often too long and the reagents are too expensive 
for rapid POC testing. Patenting and licensing-related issues have also 
slowed down the development and commercialization of the NAA 
techniques (Batchelder 2006). For these reasons, it is expected that the 
multianalyte NAA methods will be mostly used for research while 




Viruses and intracellular parasites cause strong immunoresponses, 
whereas bacterial infections usually induce a good response only 
against carbohydrate antigens, and the response involves only IgM. 
Accordingly, detection of specific antibodies is mainly used for virus 
and intracellular parasite infections. Serology is extremely useful in 
epidemiological research and in retrospective detection, in particular, 
when antigen detection methods are not applicable. On the other hand, 
the use of serology in rapid testing of acute RTIs is limited due to the 
natural delay in the immunological response and the already existing 
serum antibodies due to past infections (Allwinn 2002).  
1.2.2 Trends in laboratory testing 
Despite being overlooked in the past (Batchelder 2006), diagnostics is 
expected to be one of the most important disciplines during the 21st 
century (Fauci 2001, OECD 2003). Interestingly, only 2−5 % of 
overall health expenditures are currently used for laboratory based 
testing, despite the fact that they are the key to high-quality clinical 
care (EDMA 2003, The Lewin Group 2005). Infectious diseases 
markets are expected to grow significantly within the coming years in 
all market segments, including antimicrobial and antiviral drugs, 
vaccines, and testing (Clinica Reports 2004, Pray 2006). 
During recent years, the trend in laboratory testing of infectious 
diseases has moved from batch analysis towards random-access 
testing. The centralized approach has the drawback of a long lag time 
between the sampling and the result, and the risk of sample 
deterioration during transportation. On the other hand, centralised 
testing has the advantage of unifying and standardising the testing 
procedures. In addition, assay performance is usually superior to POC 
tests. In centralised testing, only a small proportion of overall expenses 
is usually accounted for by test reagent price, while logistics, labour 
and other indirect costs are responsible for most of the expenses. 
At the same time, the use of POC tests has increased in general. The 
trend towards POC testing can be explained by the aims of health care 
to improve patient care and cost-effectiveness by shortening turn-
around-times and by evaluating the overall cost effects (von Lode 
2005). The development of suitable technique platforms for POC is 
reinforcing this trend. 
It is likely that a balance between the two trends will be reached, so 
that clinical need and the nature of the tested analyte will determine the 
applied testing scheme (von Lode 2005). Analytes for which rapid 
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results are essential and/or for which cost-effectiveness can be shown, 
will be tested at the point-of-care. 
When rapid diagnostic methods are implemented for POC testing of 
infectious diseases an important question is whether the method(s) has 
a positive impact on the overall management of infections. The test 
should lower the economic burden caused by the disease for the 
patient, employee, or for the health care system. This is realized by 
reduced hospitalization, mortality, number of doctor visits, prescription 
of antibiotics, and spreading of infections. 
Despite the limitations of the current rapid tests methods, cost-
effectiveness and the positive impact on patient management has been 
shown (Woo 1997, Barenfanger 2000, Noyola 2000, Sintchenko 2002, 
Gerber 2004). 
Ideal test for diagnosing respiratory tract infections at the POC 
Because of the multidimensional nature of RTIs, any test that 
concentrates on only one RTI virus to the exclusion of others must 
give a biased perspective on virus diseases in general (Madeley 2007). 
Hence, such tests have very limited diagnostic impact. In addition, 
identification of one RTI pathogen should not impede testing for other 
pathogens (File 2003). Accordingly, a clear trend towards multianalyte 
methodologies can be observed in the markets. The trend is dictated by 
clinical needs as multianalyte testing is needed to allow accurate 
pathogen-specific diagnoses. A multianalyte pathogen test method for 
S. pyogenes, S. pneumoniae, and for influenza A and B, RS-, 
metapneumo, adeno, and parainfluenza viruses would be able to detect 
most of the significant respiratory infection cases. Rapid lateral flow 
tests (one or two parameter tests) for most of these pathogens are 
available. Multianalyte reagents for immunofluorescence testing that 
cover many of the viruses are also available. Neither of these 
techniques, however, is well applicable for routine multianalyte POC 
testing. 
An ideal diagnostic test for POC testing of RTIs should allow 
multianalyte pathogen testing from easily obtained samples. Most 
importantly, the product should allow accurate differentiation between 
bacterial and viral infections (Linde 2001). The test should also 
identify influenza viruses and RSV to allow targeted medication with 
specific antivirals. It would be valuable if the test also provided results 
for the other frequent viral pathogens. The clinical value of these tests 
would mainly be in ruling out more severe bacterial infections and to 
help the disease management. From the patient point of view, these 
Introduction 
 19
tests provide added value as an exact diagnosis for the symptoms can 
be obtained. Antiviral drugs for respiratory viruses other than influenza 
are expected to become available in the future. This would further 
increase the clinical value of such a multianalyte test. On the other 
hand, the lack of rapid and sensitive POC methods for many of the RTI 
pathogens constitutes a challenge for the commercialisation of virus-
specific drugs (Abed 2006). Hence, the development of antiviral drugs 
and rapid assay methods should go hand-in-hand, as a specific assay 
result is needed to justify the use of virus-specific drugs.  
Technical requirements of an ideal product for POC testing of RTIs 
include (i) ease of use, (ii) short turn-around-times, and (iii) 
robustness. The product should be (iv) suitable and designed for 
multianalyte detection, and it should provide (v) high sensitivity and 
(vi) specificity, as well as (vii) sufficient dynamic range. Results (viii) 
read-out should be automated in order to obtain unambiguous results 
and to enable (ix) connectivity to a health-care data network. The 
methodology should allow (x) quantitative analysis to better enable 
differentiation of healthy bacterial carriers from those with the disease. 
The reagents should have (xi) long shelf-life. As the success of 
sampling sets the limits for the quality of the test results, (xii) a general 
marker assessing the specimen quality would be of great value 
(Madeley 2007). So far, these objectives have not been reached by a 
single assay technique (Yager 2006). 
1.2.3 New techniques proposed for rapid point-of-care 
testing 
Commercial point-of-care compatible techniques include the Afinion 
system from Axis Shields PoC (Scotland). The Afinion concept 
consists of a bench top analyser and multi-compartment dry-chemistry 
testing cartridges. The detection system registers the transmitted or 
reflected light of the reactions, and converts it to a test result 
(www.axis-shield.com). Only modest sensitivity can be achieved using 
this technique because of the detection principle. So far, the company 
has launched tests for three blood analytes, while their clinical 
reference concentration ranges are high. Implementation of the test 
system for many of the POC analytes is limited due to insufficient 
sensitivity. The system is also characterised by high assay costs due to 
the complex cartridge design. Although the instrument can be used for 
several applications, multianalyte testing is probably not feasible. 
The Triage® system by Biosite Inc. (USA) is aimed at near-patient 
testing of drugs and proteins. This platform applies dried reagents, 
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micro capillaries, and fluorescence energy transfer assay technique 
(www.biosite.com/products/triage.aspx). The company has launched 
multianalyte tests for parasites and for profiling of shortness of breath. 
The analytical sensitivities are significantly lower compared to 
standard laboratory methods (Clark 2002). 
i-STAT by Abbott Laboratories (USA) is based on single-use test 
cartridges (www.abbottpointofcare.com/istat/index.asp). The test 
system applies enzyme conjugates and electrochemical sensors 
fabricated on a silicon chips. The cartridge wash fluid contains 
substrate for the enzyme. The product is detected electrochemically 
(amperometrically). The sensitivity of the technique reaches that of 
ELISA (picomolar level, Apple 2004). However, the complicated test 
cartridge makes the test expensive and demarcates the applications to 
those where multianalayte testing is not needed and high assay cost is 
acceptable (e.g. acute myocardial infarction testing). 
Gyrolab Bioaffy® CD microlaboratory by Gyros (Sweden) applies a 
disc-shaped microfluidic device, where fluidics is realized by 
centrifugal force, and detection is based on fluorescence 
(www.gyros.com). This technique has been shown to provide 
multianalyte detection and sensitivity comparable to ELISA, whereas 
implementation in routine use has been hindered by problems in 
sample dispensing, transfer and mixing of fluids, signal intensity, large 
size of the instrumentation, complicated assay procedures, miniaturised 
disc design, and high assay costs. 
Response Biomedical Corp (USA) has developed a RAMPTM 
technique for quantitative immunochromatography that is based on the 
use of two different antibody-coated particles with two different 
fluorophores doped inside (www.responsebio.com). One particle type 
works as an internal control and the other as a specific tracer. The 
fluorescence from both chromatography lanes is measured. The signal 
ratios are used for reducing the variation arising from membrane 
properties, environmental changes, and internal inaccuracies. The 
sensitivities are close to standard ELISA (picomolar level, Wu 2004). 
Multiplexing is propably difficult to achieve with similar performance. 
The OIA® Optical ImmunoAssay sold by Thermo Electron 
Corporation utilizes dependence of reflective properties of light from 
the mass accumulated on coated surfaces due to immunoreaction. The 
assay procedures are often multistep and, despite this, the assays are at 




Åmic (Sweden) has developed a 4Castchip that uses redesigned lateral 
flow strips. The liquid flow is driven by micro pillar capillaries instead 
of the lateral flow of chromatography paper. The detection is done by 
fluorescence. Comparable sensitivity to ELISA has been demonstrated 
(www.amic.se). Compared to nitrocellulose strips, the production cost 
of the 4Castchip is expected to be higher since it can not be processed 
in-line (O’Farrel July 2006). This arises from the fundamental 
differences between the manufacturing processes. The applicability of 
the technique for multianalyte detection remains to be shown. The 
product has not yet been launched on the markets. 
Immunobiological sensors are characterized by being label free. The 
signal measurement is based on changes in physical properties of the 
test system components. Such sensors have been developed by several 
groups. Sensors are known to have problems associated with antibody 
attachment to solid-phase, sample matrix components, reagent 
stability, sensitivity of the used enzymes for environmental changes, 
vulnerability to extrinsic factors, repeatability, non-specific binding, 
and multistep assay protocols. Current assay sensitivities seem 
adequate only for drug screening and clinical chemistry, and the price 
of the chips tends to be high. (Wild 2005) Two sensor techniques have 
evoked especially high interest within the diagnostic field. 
The SensiDXTM biosensor by Ambri Ltd sensor systems for POC 
testing is based on changes in ionic conductivity of ion channels fused 
with analyte-specific antibodies on membranes. Currently, the 
development and the commercialisation have come to a halt because of 
several drawbacks encountered (www.ambri.com). Also surface 
plasmon resonance-based biosensor techniques developed by several 
groups suffer from low throughput, poor sensitivity, high assay cost, 
and need for a washing/separation system. Thus, they are generally 
more useful in research than in clinical POC testing. 
Lab on a Chip is a term used to denote miniaturized microfluidic assay 
systems. The miniaturizing of reaction cartridges may bring several 
advantages such as faster reaction kinetics, better separation, and more 
rapid temperature changes, while the total assay system including the 
detection device may still be large (like a mass-spectrometer). Within 
recent years, lab-on-a-chip applications have been of great interest and 
have been actively developed. So far, the chips have been too 
expensive for POC applications because of the complicated chip 
designs needed to carry out the analytical tests, especially liquid 
handling and the separation of unbound reaction components (Kartalov 
2006). Sensitivities of the current techniques are sufficient only for a 
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limited number of applications. Despite the huge resources put into the 
development of these techniques, they have not yet made significant 
market breakthroughs in the in vitro diagnostic field. Instead, most of 
the microfluidistics companies are in the field of pharmaceutical and 
biotech research. Genomics are overrepresented compared to 
proteomics and clinical diagnostics (Haber 2006). 
1.3 Antimicrobial susceptibility testing 
During the last decade, antimicrobial resistance of the clinically 
relevant bacteria has increased at an alarming rate (WHO 2005). The 
most significant resistance bacterium in terms of overall economic 
impact, treatment failures, and workload is methicillin-resistant 
Staphylococcus aureus (MRSA) (Gould 2005). S. aureus is often 
found in the human flora. However, as a result of trauma and the 
subsequent failure of the immune system to control the infection, the 
bacterium may cause clinical infections. For effective infection 
management in hospital, all patients at increased risk of MRSA 
carriership should preferably be contact isolated until tested negative 
(Kotilainen 2003). 
MRSA strains are not necessarily more pathogenic than susceptible 
strains, but the treatment of MRSA infections is more demanding and 
expensive. It seems that MRSA infections have double the mortality of 
susceptible strain infections, at least partly explained by the 
inappropriate empirical treatment. The economic burden of resistant 
microbes arises mainly from indirect costs of morbidity and 
diminished quality of life; and from surveillance and control activities, 
including disinfection, patient contact isolation, and decontamination. 
Additional costs of MRSA infections amount to thousands to tens of 
thousands of dollars per hospitalized patient. (Gould 2005) 
1.3.1 Methods based on culture 
Conventional methods for antimicrobial susceptibility testing (AST) 
rely on microbial culture. These phenotypic methods usually have 
good correlation with the in vivo response of the drug. Culture methods 
are flexible and can be applied with minor modifications to new 
antimicrobial resistance strains. Standard disk-diffusion tests, Etests 
and broth dilution methods are, however, labour-intensive and prone to 
subjective observation. They also have long turn-around-times. 
Instrument development has aimed at shortening hands-on-times and 
increasing the reliability of the tests by automation (Felmingham 
2001). Despite these efforts, turn-around-times of the assays have not 
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essentially decreased, since the methods still require the samples to be 
pure cultured isolates. New methods have been introduced in recent 
years but most of them still use culture at some point of the work flow. 
1.3.2 Methods based on immunoassay 
Immunoassay AST methods can apply different methodologies. Some 
of the methods are indirect and based on the correlation between 
certain antigens and phenotypic resistance. Because these antigens are 
usually not species-specific, the methods require pure culture of the 
samples. Rapid tests for MRSA usually detect protein PBP2a 
(alternative penicillin binding protein) which is involved in the cell 
wall synthesis (Hartman 1984). The protein has lower affinity for most 
β-lactam antibiotics compared to native PBP proteins, and this inhibits 
the antibiotic activity. Thus, detection of this protein is indicative of a 
resistant strain. Unfortunately, coagulase negative bacteria show the 
same resistance mechanism, and therefore pure culturing is needed 
prior to detection (van Leeuwen 1999).  
Another principle relies on rapid identification of the bacterium after 
the culturing of pure cultured strains in the prescence of antibiotics. 
The tests for MRSA detect one or several target antigens 
simultaneously, such as clumping factor, protein A, group-specific 
antigens, and capsular polysaccharides (Wichelhaus 1999). Most of the 
tests rely on latex agglutination. 
Very recently, a new test for rapid screening of MRSA, the BacLiteTM 
Rapid MRSA Test, was introduced by 3M (www.3m.com). The test 
allows analysis directly from clinical samples within 5−24 hours. In 
the test, samples are first cultured in microtitre wells using a selective 
liquid growth medium. Then S. aureus cells are extracted with 
antibody-coated particles and further cultured in the presence of the 
antimicrobial. Finally, the cells are lysed and adenylate kinase activity 
is measured using bioluminescence. In contrast to conventional 
methods, this approach allows MRSA screening directly from clinical 
samples due to the extraction with antibody reagents. Similar AST 
approaches based on ELISA are known to be in in-house use, although 
the number of scientific reports and commercial tests applying the 
principle has so far been low. A major reason for this might be the 
need for washes and multistep assay protocols (including the test by 
3M). In consequence, such tests do not provide significant 




1.3.3 Methods based on nucleic acid amplification 
Genotypic methods are based on detection of determinants of the 
antimicrobial resistance at the genetic level and apply nucleic acid 
amplification (NAA). This approach is based on the correlation 
between genetic sequences and phenotypic antimicrobial resistance. 
Development of these methods has been driven both by the clinical 
need for rapid diagnostic tools and the increasing knowledge about 
genetic properties of the pathogens. 
Most of the genetic methods for MRSA rely on testing for the mecA 
gene that encodes the PBP2a protein. Most coagulase negative bacteria 
have also the mecA gene, and they are abundant in clinical samples 
(Hyvärinen 1995). Thus, detection of genetic material of S. aureus, and 
the mecA gene directly from the screening specimen (not pure 
cultured) is not reliably indicative of MRSA infection (Becker 2006). 
Hence, pure culture is usually needed. Just recently, genetic methods 
that allow identification of MRSA directly from clinical samples have 
been developed. The detection of the mecA gene in these methods is 
linked with the detection of S. aureus specific genes from the same 
physical genome (Huletsky 2004). 
Some authors believe that the NAA methods are about to replace the 
conventional phenotypic methods, and see them as alternatives or 
competitors with each other (Global Industry Analysts). However, the 
methodologies have different strengths and limitations, and they give 
answers to different analytical and clinical questions.  
In principle, the NAA methods have very high analytical sensitivity 
and specificity in the detection of potential resistance genes. However, 
correlation to in vivo antimicrobial susceptibility can be poor. The 
presence of a resistance gene does not necessarily lead to treatment 
failure or vice versa. Poor correlation can arise from varying 
expression levels, or the resistance sequence can be from a silent or 
pseudogene (Sundsfjord 2004). On the other hand, the NAA methods 
may be superior compared to conventional culture in detecting 
heterogenically resistant strains. 
The final steps of NAA and detection of the copy products can be 
seemingly rapid. This speed and the accuracy of finding certain 
resistance genes have been used to justify testing with NAA methods, 
which are more expensive than the phenotypic methods. Most of the 
NAA methods have so far required the sample to be pure cultured 
isolate, and the nucleic acid to be in extracted form. Hence, the 
sampling to result time has shortened only a little. In general, market 
entry of NAA methods has been markedly slower than was anticipated 
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some years ago (Global Industry Analysts). With the advent of new 
NAA methods that allow genetic testing directly from clinical samples, 
the applicability of the methods is expected to increase significantly.  
Genetic testing is based on the testing of resistance determinants, 
whereas the antimicrobial therapy decision should be based on 
detection of susceptibility (Sundsfjord 2004). Genetic methods are 
searching for what is already known. Gathering genetic understanding 
about a pathogen to construct a method has so far required huge 
research efforts. For these reasons, genetic methods are best suited to 
epidemiology, screening, confirmatory purposes, and for research, 
rather than for patient-specific medication. Genetic methods are 
suitable for testing known strains, and the results should be analysed 
carefully when making treatment decisions. Thus, conventional 
phenotypic methods can not be expected to be supplanted by NAA 
methods (Sundsfjord 2004). Phenotypic methods are needed to detect 
emerging new resistance mechanisms, and to obtain clinically accurate 
data (Fluit 2001, Sundsfjord 2004). 
1.4 Clinical phase of an infection 
1.4.1 Systemic markers of acute infection 
There are several systemic markers with concentrations correlating 
with the acute phase of inflammatory and immune systems, and they 
can be used in evaluation of the infection phase. They are also used in 
differential diagnosis of viral and bacterial infections (see 1.2.1.1). 
Positive test results should usually be followed by more specific 
clinical examination and laboratory tests. 
1.4.2 Specific markers of infection 
To enable high clinical accuracy of diagnoses, patients should be tested 
for disease-specific markers. When direct pathogen detection is not 
feasible, the most accurate results are provided by pathogen-specific 
antibodies (serodiagnostic testing). In screening applications, a 
qualitative test result is often sufficient. In other applications, more 
detailed quantitative information is needed in order to differentiate 
between primary, secondary and past infections. 
Class-specific detection 
In serodiagnostic testing, the infection phase and clinical status are 
usually determined by class-specific analysis of antibody responses. 
Although class-specific methods are widely used, they are known to 
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sometimes have poor correlation with the clinical phase of the 
infection. Methodological limitations include proneness to matrix 
interference caused by auto- and heterophilic antibodies (such as 
rheumatoid factor and inter-species antibodies), and by the 
complement. In addition, the signal response is contributed to by both 
the antibody concentration and the variable affinity distribution of the 
antibody population. For this reason, traditional coated-tube techniques 
do not allow quantitative measurements of specific antibody 
concentrations. (Lehtonen 1982)  
Clinical diagnosis based on the relative amounts of IgM and IgG is not 
always reliable due to inter-individual variation. In some patients, the 
primary IgM response may remain below the detection limit of the 
method, while in other patients, the IgM response can persist for years 
(Hedman 1989, Andersson 1994). Moreover, false positive detection of 
IgM can occur due to non-specific polyclonal activation (Meurman 
1983, Thomas 1999, Roque-Afonso 2004). In addition, the scheme of 
the response may depend on the pathogen. Sometimes IgG-class 
antibodies are detectable in primary infection already during onset of 
symptoms (Hedman 1991). 
In order to allow more reliable clinical diagnosis, class-specific 
methods often require paired sample analysis, in which changes in the 
abundance of specific antibodies in two consecutive samples are 
compared. The long delay in diagnosis limits the clinical value of the 
technique. Obtaining a laboratory diagnosis when the symptoms and 
the infection have already resolved does not allow optimal treatment.  
Antibody bridging assay principle 
Getting rid of washing steps has been a long cherished goal in the 
development of bioaffinity assay techniques. A fundamental problem 
of the wash-free methods is that they do not usually allow class-
specific serology. The reason for this is that only small fractions (in the 
order of one tenth of a percent) of the antibodies in a certain isotype 
class are specific for a particular antigen. The majority of the isotype 
represent specificities to other antigenic species. The non-specific 
fraction is usually in huge excess to the immunoassay reagent. Hence, 
in one-step assay methods the non-specific antibodies will, in practice, 
saturate all the anti-immunoglobulin reagent binding sites. For this 
reason, class-specific detection requires separation of the non-specific 
isotype fraction before addition of the second immunoassay probe. 
An alternative assay scheme for class-specific detection is antibody-
bridging (AB). In this binding scheme, specific antibody molecules 
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(analyte) bind with one arm to the antigen in the solid phase, and with 
another arm to a labelled antigen reagent. Thus, the antibody 
molecules form a bridge between the two separate antigen molecules. 
In the industry, the principle is known to provide excellent 
performance, and it is applied in several commercial immunoassay 
products such as PrismTM, ElecsysTM, and Centaur® platforms. 
However, the number of published scientific articles is very low 
compared to class-specific methods.  
The AB assay principle has several advantages compared to traditional 
class-specific techniques, including resistance to interference caused 
by matrix effects (Siitari 1990, Bürgisser 1996, Ankelo 2003), superior 
specificity (Miyazawa 1988, Siitari 1990, Bürgisser 1996, Horimoto 
1997, Miyazawa 1999), low non-specific binding (Chang 1984, 
Horimoto 1997, Miyazawa 1999, Ankelo 2003, Westerlund-Karlsson 
2003), and freedom from bias caused by differences in the affinities of 
anti-immunoglobulin reagents. The assay principle may also provide 
high sensitivity for IgM-class antibodies, allowing earlier detection of 
an immune response (Chang 1984, Gallarda 1992, Bürgisser 1996). 
The antibody-bridging principle per se does not allow differentiation 
between primary and secondary or past infections, and this has been 
considered the main drawback of the assay principle. 
Measurement of antibody avidities 
Avidity index (AI) assay methodology in its various modifications is 
based on determination of the avidity distribution of the antibody 
population in the sample. It is an alternative approach to class-specific 
assessment of the infection phase, i.e. to differentiate between primary, 
secondary and past infections (Pullen 1986, MacDonald 1988, Hedman 
1993). In primary infection, the avidity distribution is wide, and the 
avidities are low, on average. Secondary and past infections, in turn, 
are characterised by a narrow avidity distribution, and high avidity. In 
the avidity index technique, the sample is exposed, in parallel, to a 
normal assay buffer and to a buffer containing a chaotropic agent. The 
ratio of the two results gives the avidity index. The higher the average 
avidity of the antibody population, the larger the proportion of solid-
phase bound analyte antibodies able to remain bound with the antigen 
in the presence of the chaotrope. Alternatively, the chaotrope can be 
present already in the primary sample incubation buffer where it 
prevents the binding of low avidity antibodies. If the AI exceeds an 
analyte-dependent threshold, the infection can be deemed past or 
secondary. (Thomas 1991, Hedman 1993) When the AI information is 
combined with the signal levels of the serodiagnostic method 
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(proportional to concentration), reliable estimates of the nature and 
phase of the infection can be made from a single clinical sample. The 
AI method does not require analysis of paired serum samples. 
The suitability of the AI technique for differentiation between primary 
and secondary phase immunoresponses has been comprehensively 
demonstrated in the literature for many pathogens (Hedman 1993, 
Granoff 1998, Korhonen 1999). The AI technique provides good 
clinical performance compared with traditional class-specific methods. 
Despite the advantages of the AI technique, it is applied less widely 
than the class-specific methods at present. One explanation for this is 
that many of the methods must apply the so-called end-point titre AI 
determination, which is needed to obtain reliable AIs. In IgG AI 
techniques the obtained AI is often dependent on IgG concentration 
(used titre). Due to the high price of such tests in heteregenous assay 
platforms, the technique is mainly used in confirmatory tests. 
1.5 Two-photon excitation assay technique 
Recent developments in in vitro diagnostic testing have aimed at 
physical downsizing, simplified protocols, automated random-access 
operation, speed, and adaptability for point-of-care testing. An ideal 
technique would avoid physical separation steps and its performance 
would be independent of the reaction volumes. These should be 
achieved without compromises in accuracy, cost-efficiency, or 
reliability. Usually some goals are achieved at the expense of others. 
The two-photon excitation (TPX) assay technique is a novel micro-
analytical bioaffinity technique that potentially fulfils the above 
mentioned criteria. The technique applies polymer microspheres as 
solid phase carriers for bioaffinity binding reactions (Figure 1). The 
microparticles (3 000 per µl) act as local concentrators for the 
fluorescent tracer molecules (present in 1 nM concentration). The 
tracer concentrates on the solid surface according to the immunometric 
principle. The detection of the formed complexes is based on two-
photon excited fluorescence measurement of individual microparticles. 
(Soini 2002a) Fluorescence is excitated with a pulsed near infra-red 
laser (1064 nm), while the fluorescence from individual microparticles 
is measured at visible wavelengths (Hänninen 2000, Soini 2000). 
Most luminescence techniques use single-photon excitation where the 
wavelength of the illumination (excitation) is shorter (higher in energy) 
than the fluorescence emission. Such techniques usually have 
relatively large excitation volumes, and their signal is directly 
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proportional to the measurement reaction volume. Excitation with two 
simultaneous photons, in contrast, takes place only when the density of 
photons per unit volume and per unit time is high enough for two 
photons to be simultaneously absorbed by the same fluorophore. The 
absorbed energy is the sum of the energies of the two photons. This 
leads to a situation where two-photon excitation is achieved only in a 
volume that corresponds approximately to the size of a microsphere 
(~1 fl). The excited state is relaxed by emission of a photon of higher 
energy (shorter wavelength) compared to the illumination (Figure 2). 
 
Figure 1. Schematic presentation of the immunocomplex formation between 
the solid phase and the tracer reagents with the analyte. 
 
Figure 2. Left side shows a simplified Jablonski energy diagram for single- 
and two-photon excitations, and for emission (quantum nature of light). Right 
side presents schematically the wave nature of light in single- (up-right) and 
in two-photon (low-right) excitation. 
In the TPX technique, discrimination of the fluorescence signal of the 
microsphere-bound tracer from the unbound tracer in solution takes 




















the reaction mixture for microspheres, which are then trapped in the 
focus for less than 100 ms. The presence of a microsphere within the 
focal volume is indicated by the excitation light scattering signal in the 
infra-red region (Soini 2002a, Soini 2002b). When scattering is not 
detected, the signal is averaged for the solution background signal. 
When scattering is observed according to certain parameters and the 
microsphere is trapped in the focus, the signal is averaged for the 
microsphere signal. Accordingly, the optical system of the fluorometer 
separates the fluorescence of the bound tracer from the fluorescence 
originating from the unbound tracer free in solution. This enables the 
measurement of bioaffinity reactions without physical separation of the 
unbound tracer fraction. Hence the term, separation-free. 
In two-photon excited fluorescence, excitation and emission take place 
in totally different wavelength ranges. For this reason, scattering of 
illumination light and fluorescence from optical components can be 
effectively eliminated by optical filtering. The measured signal is 
practically free of the scattering and the background fluorescence of 
the excitation. In practice, the background signals are governed by the 
concentration of the tracer free in solution, and not by the unspecific 
binding or instrument background as in coated-tube technologies. 
Because of the extremely small excitation volume, the measured 
fluorescence signal, as well as the sensitivity and precision are 
independent of the reaction volume. Reagent consumption is very low 
because of low concentrations and small volumes. The separation-free 
assay format allows on-line monitoring of reaction kinetics (Hänninen 
2000). Separation-free fluorescence measurement minimizes the need 
for automated liquid handling. A further advantage of the technique is 
that the microfluorometer provides information both from the 
microspheres and from the surrounding solution. This allows efficient 
flagging out and/or compensation of matrix effects. 
When a molecular tracer is used, the sensitivities of immunometric 
assays are typically 1−10 pM, depending on the antibody affinities. 
The use of a nanoparticulate tracer enables sensitivities well within the 
femtomolar range (Koskinen 2004, Koskinen 2007). The TPX assay 
technique applies fluorescent labels which have been specially 
designed for two-photon excitation fluorescence (Meltola 2005c). 
The TPX assay technique has been applied for a wide selection of 
bioaffinity assay types including antigens (Waris 2002), antibodies 
(Koskinen 2006), competitive binding assays (Vaarno 2003, Tirri 
2005), recognition of nucleic acid sequences (Meltola 2005b), and 
single nucleotide polymorphism (Vaarno 2004). 
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2 Aims of the study 
The continuous increase in drug-resistant microbe strains and the new 
virus-specific drugs will most likely lead to new more strict 
recommendations concerning the prescription of medication. The new 
recommendations are expected to call for in vitro identification of the 
pathogen before prescription. These will increase the need for new 
diagnostic tools which are adaptable for rapid point-of-care testing of 
infectious diseases. None of the mainstream rapid POC techniques 
allows efficient multianalyte detection, which is needed for efficient 
diagnostic testing of respiratory tract infections. The POC techniques 
used today no longer meet the requirements of today’s healthcare 
delivery models (OECD 2003). Accordingly, the most urgent need for 
new rapid POC tests in the field of infectious diseases testing is in the 
segment of respiratory tract infections. 
The purpose of this study was to evaluate the potential of two-photon 
excitation fluorometry as a diagnostic technique for rapid point-of-care 
testing of infectious diseases. 
In more detail, the aims of this study were: 
1. To study how the TPX technique is suited to high sensitivity 
detection of systemic markers of acute infections. 
2. To study how sensitivity of the technique could be increased. 
3. To study how the assay protocols of the technique could be 
further simplified. 
4. To study the applicability of the technique for serodiagnostic 
testing. 
5. To study the use of the technique for rapid testing of infectious 
diseases. 
6. To study the suitability of the technique for real-time monitoring 
of microbial growth, and for antimicrobial susceptibility testing. 
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3 Materials and Methods 
3.1 Materials 
Most of the used chemical reagents, buffer compositions, antibody 
clones, antigens, and description of the clinical samples have been 
given in detail in Publications I-V. Those not described, are listed here. 
EDAC-sulfo-NHS-solution: 20 mM EDAC (N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride), 200 mM 
sulfo-NHS (N-hydroxysulfosuccinimide sodium salt) in 25 mM MES 
(2-(N-morpholino)ethanosulfonic acid) buffer. Glycine-BSA -solution: 
100 mM glycine, 1 % BSA (bovine serum albumin), pH 8.5. BSA 
solution: 10 mM Tris-base, 0.01 % Tween 20; 20 % BSA, and 10 mM 
NaN3, pH 8.0. Nanoparticle gel filtration -buffer: 10 mM Tris-base, 10 
mM NaN3, and 0.01 % Tween 20, pH 8.0. Nanoparticles (co-polymer 
of styrene and acrylic acid, diameter 55 nm, solid content 5 %) were a 
generous gift from Dr. Harri Härmä (University of Turku, Finland), 
and were prepared as described earlier (Huhtinen 2005). Dialysis tubes 
(Spectrapor Dispodialyzer cut off 10 kilodalton) came from Spectrum 
Laboratories Inc. NAP-5 and Superdex 200 (preparative grade) gel-
filtration columns came from Amersham Biosciences Inc. The 
Nanosep centrifugal device (Omega 300 kilodalton) was from the Pall 
Corporation (NY, USA). 
3.2 Methods 
Coating of microspheres 
Coating protocols for the microsphere reagents have been described in 
Publications I-V. Typically, antibody (0.2 mg/ml in 50 mM MES 
buffer pH 5.5) coating was done by passive adsorption to the 
microsphere surface (1.5 µg of protein / cm2 of diameter 3.2 µm 
microsphere surface) followed by fixation with EDAC in 50 mM MES 
buffer pH 5.5 (0.5 mg/ml). EDAC cross-links free amine groups of the 
proteins to carboxylic acid groups of the proteins and the microsphere 
surface. This makes the microsphere reagents less susceptible to 
protein leaking. It also improves their binding capacity. Antigens were 
coated either using a similar method or via a biotin-avidin linkage 
(III). 
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Labelling of antibodies and antigens 
Antibodies and antigens (2 mg/ml in 100 mM NaHCO3, pH 8.4) were 
labelled with succinimidyl ester of the fluorescent labelling reagent BF 
530 as described by Meltola et al. (2005a). The reagent binds 
covalently to free amine groups of the target protein molecules. After 
three hours of incubation (at room temperature, in dark) the protein-
fluorophore conjugate was separated from the unreacted fluorophore 
by using size exclusion chromatography (NAP-5 column, phosphate 
buffered saline). The protein specific parameters (concentration of the 
labelling reagent) and the resulting conjugation degrees have been 
described in Publications I-V. For IgG, the optimal conjugation degree 
(fluorophores per protein molecule) as evaluated by immunoassay 
performance (sensitivity) was four fluorophores per molecule, and for 
other proteins, it was scaled in relation to the molecular weight. 
Preparation of nanoparticle tracers 
A solution of methyl ester derivative of the fluorescent dye ArcDiaTM 
BF 530 (500 µl, 2 mg/ml in dimethylformamide) was slowly added to 
a suspension of nanoparticles (500 µl of the stock supernatant) while 
vortexing. The mixture was incubated at +6°C for one day, and water 
(1 ml) was added. The mixture was transferred to a dialysis tube, and 
dialyzed against 1 litre of 50 % ethanol and water. The nanoparticle 
solution was transferred to a glass tube for storage, and NaN3 was 
added to the final concentration of 10 mM. The solid content of the 
resulting solution was 0.5 % (7.3 x 1016 particles/l). The nanoparticle 
solution was analysed with a photon correlation spectrometer (Coulter 
N4 Plus submicron analyser, Beckman Coulter Inc., Fullerton, CA, 
USA). This indicated a mean nanoparticle diameter of 55 nm. 
Equal volumes (240 µl) of fluorescent nanoparticles (1200 µg solid) 
and MES buffer (50 mM) were combined. To this solution, a 1/10 
volume unit of freshly prepared EDAC-sulfo-NHS-solution was added 
while vortexing, and the reaction was bath-sonicated for 30 seconds. 
The reaction mixture was stirred in the dark at room temperature 
(Eppendorf ThermoShaker, 1400 rpm) for 10 minutes, sonicated again 
for 30 seconds, and stirred for another 10 minutes. The reaction 
mixture was eluted through a NAP-5 column with MES buffer (25 
mM). The solution was concentrated to a volume of 240 µl by 
centrifugation with Nanosep (300 kilodalton). An aliquot (40 µl, 200 
µg solid) of this solution was added drop by drop to monoclonal 
antibody solution in carbonate buffer (120 µl, 2.5 mg/ml) while 
vortexing. The solution was bath-sonicated for 30 seconds, and stirred 
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at room temperature for 6 hours. One volume of glycine-BSA solution 
(160 µl) was added to the solution while vortexing, and stirring was 
continued overnight at 10°C. The solutions were gel filtrated (1 
ml/min, Superdex 200 preparative grade) with Merck Hitachi HPLC 
(High performance liquid chromatography) using gel-filtration buffer. 
Prior to the gel-filtration, the solutions were bath-sonicated for 15 
seconds. Fractions (á 330 µl) containing the antibody-coated 
nanoparticles were combined. BSA solution was added to the final 
concentration of 0.25 %. The concentration of the solution was 
determined by fluorometry in relation to the original stock. The size 
distribution of the nanoparticles was determined with Coulter N4 Plus. 
Preparation of dry-chemistry reagent assay plates 
Method specific assay protocols, preparation of assay reagent mixtures 
(I-V) and dry-chemistry assay wells (II, IV, and V) have been 
described in detail in the original Publications. Typically, equal 
volumes of microsphere and tracer predilutions (2−4 x 107 pieces / ml, 
and 2−4 nM for molecular and 10−50 pM for nanoparticle tracers, 
respectively) in dry-chemistry assay buffer were combined, and 
dispensed (5 µl) with an automate dispenser onto 384-well plates, 
followed by drying over silica gel in a desiccator with a fan (at room 
temperature, in dark, over-night) (II, IV, and V). The plates containing 
the reagents in the dry form were stored in laminated foil bags with 
silica gel until use. 
Typical assay protocol 
For an assay, a dry-chemistry reagent plate is removed from the 
storage bag, an appropriately diluted sample in assay buffer is 
dispensed (20 µl) onto the wells, and the wells are sealed with a plate-
sealing film. The plate is inserted into an ArcDiaTM TPX Plate Reader 




4.1 Preparation and optimization of 
immunoassay reagents 
The protocols for antibody coating (Waris 2002) and protein labelling 
(Meltola 2005a) used in this work usually provided excellent assay 
reagents (I-V). Further optimization of coating conditions (such as pH) 
rarely improved assay performance (unpublished results). This 
indicates the robustness and wide applicability of the coating 
methodology. For optimal coating of antigens, however, it turned out 
that biotin-(strept)avidin coating is often needed to maintain high 
immunological activity (III). For IgG-molecules, the optimal labelling 
degree turned out to be four fluorophores per antibody molecule (IV) 
which is in line with previous results (Meltola 2005a). The 
protein−fluorophore conjugates (ArcDiaTM BF530, Meltola 2005c) 
demonstrated stability and good performance. 
Optimization of assay microsphere and tracer concentrations was done 
by cross-testing different concentrations of the reagents (in reaction 
1.5−5×106 microspheres/ml and 0.25−4 nM tracer) (I−V). The 
theoretical and practical aspects of optimization are discussed in 
Publication V. Most often close-to-optimal assay conditions can be 
selected on the basis of previous experience. Usually, only a modest 
improvement (a factor of two) can be achieved by further optimization 
of the concentrations. Nevertheless, cross-testing of different reagent 
concentrations on the TPX platform is easy due to simple assay 
protocols. The on-line measurement option provides an easy means to 
optimize the concentrations also with regard to assay kinetics. 
During the method development work, reagent antibody clones were 
typically optimized by testing a number of different antibody clones in 
all feasible combinations. For the influenza B virus method, clone 
optimization was needed because the antibodies applied in the 
reference method did not provide good sensitivity in the TPX platform. 
Despite the testing of seven different antibody clones, the method 
failed to provide sufficient clinical sensitivity with the molecular 
tracer. Hence, we had to apply a nanoparticulate tracer approach which 
was also optimized with respect to antibody clones (IV). According to 
our experience, the performance of antibody clones can vary 
significantly by detection platform (IV) and by tracer type (molecular 
versus nanoparticulate tracer, Appendix 2). 
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4.2 Dry-Chemistry reagents 
The development and use of dry-chemistry reagents is described in 
Publications II, IV, and V. The common drying protectants, sorbitol 
and trehalose turned out to be compatible with the reagents of the TPX 
technique. Rapid and thorough dissolving of the dry-chemistry 
reagents, especially the microspheres, required efficient shaking of the 
assay plate. Once well shaken, the dried reagents were rapidly 
suspensed (II). Inclusion of the drying protectants in the wet-chemistry 
reagents did not affect the immunoassay kinetics (unpublished 
results). Based on these observations, it is safe to assume that in 
clinical point-of-care testing, the dry-chemistry reagents give as rapid 
and as sensitive results as the wet-chemistry reagents. The use of dried 
reagents allowed markedly simplified assay protocols (one-step). 
In Publication IV, the dry-chemistry reagent approach was applied 
successfully also for a nanoparticulate tracer. This was expected to be 
challenging because of potential problems in colloidal stability and in 
unspecific binding, which tend to increase in conventional coated-tube 
techniques. The dry-chemistry reagents provided the same clinical 
results as the original wet-chemistry method. The wet- and the dry-
chemistry methods also showed excellent signal correlation between 
each other for the clinical samples. Pearson correlation coefficients for 
influenza A and B virus methods were 0.97 with P<0.0001, and 0.96 
with P<0.0001, respectively.  
In Publication V, the dry-chemistry reagents were applied in a method 
for antimicrobial susceptibility testing of S. aureus. Both the anti-
microbial agent and the immunoassay reagents were dried onto the 
reaction wells. Also in this application, the dry-chemistry reagent 
method gave the same results as the corresponding wet-chemistry 
reagent method. The dry-chemistry reagents retained their 
functionality during a stability testing period of three months (II, IV). 
Unexpectedly, unspecific binding was not observed with the dried 
reagents despite the solid phase microspheres, and the tracer were 
stored in the same physical protective medium (II, IV, V). When dried 
reagents are applied in heterogeneous assays formats, such as TR-FIA, 
the tracer must be physically separated from the solid phase in order to 
minimize unspecific binding. 
4.3 Nanoparticulate tracers 
The detection sensitivity (lowest limit of detection) achievable with 
conventional molecular tracers in the TPX detection technique is 1-5 
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pM. This sensitivity, however, is not sufficient for all the clinically 
important analytes. For example, human thyroid stimulating hormone 
(hTSH, Appendix 2) and cardiac markers require subpicomolar 
detection sensitivity. In Publication I, we described a sensitive assay 
method for human C-reactive protein (CRP) that applied a 
nanoparticulate tracer (NPT). These NPTs were custom-made by a 
collaborator. The objective was to develop a method for the detection 
and monitoring of systemic inflammation/infection markers. The 
nanoparticulate tracer improved the detection sensitivity compared to 
the molecular tracer method by two orders of magnitude. The assay 
showed a dynamic assay range of 0.01−30 mg/L. The sensitivity was 
significantly better compared to most commercial methods (Roberts 
2000). The method applied a total serum sample dilution factor of 
1 000; thus the detection limit in the reaction mixture was 10 pg/ml (90 
femtomolar). (I) If higher CRP levels are to be measured, more diluted 
samples must be used. 
Subsequently, the CRP method has been used for studies of diabetes 
(Waris 2005), multiple sclerosis (Soilu-Hänninen 2005), 
photochemical photobiology (Laihia 2005), and general immunology 
(Koskinen 2003). A major clinical finding in these studies was that the 
serum CRP levels of healthy individuals were markedly lower (0.1-1 
mg/L) compared to previous understanding (I, Koskinen 2003). 
Another interesting finding was that the serum CRP levels were 
sensitive even to the slightest inflammation conditions, such as 
sunburns and common flu (Koskinen 2003, Laihia 2005). To allow 
reliable assessment of general inflammation marker baseline levels, 
several consecutive samples, separated by at least a few weeks in time, 
should be analysed. 
Despite extensive optimization of influenza B virus methods using a 
molecular tracer, this method failed to provide sufficient clinical 
sensitivity (IV). It is well known that assay methods for influenza B 
virus antigen detection are generally characterized by lower clinical 
sensitivity compared to methods for influenza A virus. In order to 
improve the performance of the influenza B virus method we chose to 
apply NPTs. Since the performance of a NPT is heavily dependent on 
the antibody properties we studied five alternative monoclonal 
antibody clones, and tested them against seven antibody clones on the 
microspheres. The most promising combinations were further 
optimized with respect to NPT concentrations. 
For the preparation of nanoparticulate tracers, polystyrene 
nanoparticles were first impregnated with two-photon excitable 
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fluorophores. Based on fluorescence intensity measurements, each 
nanoparticle contained 250 fluorophores, while the effective 
fluorescence yield corresponded to the fluorescence of 150 molecules 
(unpublished data). For coupling with anti-influenza B virus 
antibodies of different clonalities, carboxylic acid groups on the 
fluorescent nanoparticle surface were activated using two-step EDAC - 
sulfo-NHS activation. After the coating with the antibodies, glycine 
and bovine serum albumin were added to deactivate the unreacted 
carboxyl groups and to block free sites on the polystyrene surface, 
respectively. Unconjugated antibodies were separated from the 
nanoparticle antibody tracer by size exclusion chromatography. 
Aggregation is a common problem with nanoparticles. Aggregation 
results in higher signal variation and tends to increase unspecific 
binding. These compromise assay sensitivity and impair precision. 
During the NPT development, all the physical steps were chosen so as 
to minimize the aggregation of the nanoparticles. For example, gel-
filtration was used instead of centrifugal filter devices. Conjugates 
showed rather narrow size distribution in photon correlation 
spectrometry, whereas mean diameters between the clones showed 
more significant variation (see IV). Typically, the diameters of the 
NPTs were 100−200 nm (before coating 55 nm) which is in line with 
the results reported by others (Soukka 2003). Thus, the NPTs seemed 
to consist of small aggregates of few nanoparticles. Passive adsorption 
methodology applied in initial studies resulted in significantly larger 
aggregates. Those NPTs showed slower kinetics and lower sensitivity. 
The NPT method showed markedly increased signal-to-background 
ratios (a factor of 3–10), compared to the molecular tracer method. 
This allowed rapid detection of influenza B virus antigens. We also 
studied the applicability of the dry-chemistry reagents with the NPT 
reagent, and found that they could be stored dried without 
compromising the assay performance. (IV) 
Usually, the signal imprecision of assay methods based on the TPX 
detection technique is independent of the analyte concentration. The 
NPT methods, and especially the method for influenza B virus, made 
an exception by showing a clear trend. Low analyte concentrations had 
higher imprecision (IV). The trend might be explained by molecular 
level phenomena as with high analyte concentrations, MT and NPT 
signal imprecisions were similar. Influenza B virus antigens are most 
probably in the form of large antigen complexes composed of 
nucleoprotein and nucleic acid. The binding of antigen complexes and 
NPT reagent to microspheres thus follows the Poisson distribution. 
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Hence, when the amount of nucleoprotein complexes approaches the 
number of microspheres (about 5−50 per microsphere), the number of 
bound NPT per microsphere varies by tens of percents. Also, variation 
in the number of nanoparticles per reagent aggregate should manifest 
itself in this manner. This trend was not observed with the NPT for 
CRP (I), most probably because this reagent (and the CRP analyte) 
was uniform and had narrow size distribution. In contrast to other NTP 
reagents, CRP tracer was prepared by coating the nanoparticles with 
F(ab)2-fragments (instead of IgG). In our experience, coating with Fab-
fragments results in smaller nanoparticle tracer conjugates compared to 
intact IgG´s of the same antibody clone (unpublished data). This is 
probably due to the lower tendency for an unspecific interaction as the 
Fc-fragment is more hydrophobic than the Fab-fragments. 
4.4 Antigen detection of respiratory tract 
pathogens 
Publication IV describes the development and validation of methods 
for rapid detection of influenza A and B virus antigens from nasal 
specimens. The performance of the methods was compared to TR-FIA 
reference methods. The new methods were tested using both wet- and 
dry-chemistry assay reagents. The wet-chemistry reagent assays were 
carried out using the kinetic measurement option to evaluate the 
positive detection rate, defined as a fraction of the samples deemed 
positive at a certain time point. 
The key results of Publication IV were (i-vi): 
(i) A rapid method for detection of influenza A virus antigens was 
developed and validated. At the 20-minute incubation time point, 
23 out of 24 positive samples were determined as positive by the 
new method, while two borderline samples remained negative at 
this time point (Figure 4). At 60 minutes, all of the positive and 
borderline samples were deemed positive (sensitivity 100 %). In 
addition, the new method found one extra positive sample 
compared to the reference method. This sample was positive also 
in PCR. Furthermore, one sample which was TR-FIA positive but 
PCR negative was found negative in TPX. No cross-reaction was 
found to influenza B virus positive samples, indicating a 






















Figure 4. Performance of the method for influenza A virus detection at the 
20-minute time point. The dashed line represents the cut-off value set for a 
positive test result. 
(ii) A sensitive method for rapid testing of influenza B virus antigens 
was developed and validated. According to the results, at 25 
minutes of incubation, 25 out of 25 positive samples were 
determined as positive, and four borderline samples were tested as 
negative (Figure 5). At the time point of 120 minutes, two of the 
four borderline samples barely cut the analytical detection 
threshold (intra-assay 3SD) set for positive detection in TPX, 
while these samples did not reach the method-specific cut-off 
(inter-assay 3SD). Of the two samples that remained negative in 
TPX one was positive by PCR and the other was negative by PCR 
(false positive in TR-FIA). No cross-reaction was found to 
influenza A virus positive samples, indicating a specificity close 
to 100 % (N = 36). 
(iii) The results showed that the wet- and the dry-chemistry reagent 
methods provided the same results for each patient sample. Also 
application of NPT as dried reagent provided good performance 
without compromising sensitivity, kinetics, or precision. 
(iv) The methods were validated by running a large number of clinical 
samples that included interfering matrix components. The results 
showed that the technique is robust and tolerates particulate 
material, mucus, and haemoglobin well. The TPX technique has 
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the unique property of giving separate information about the 
specific immunoreaction (microsphere signal), and about the 
matrix effects (solution background signal). This allows 
compensation and/or flagging out of the matrix effects. 
(v) Due to the on-line measurement, most of the positive samples 
(about 90 %) can be detected rapidly within 20 minutes. This is 
possible without compromising in the overall assay sensitivity as 
the confirmation measurement is done after 2 hours of incubation 
(immunoreactions close to equilibrium). 
(vi) The TPX technique would allow rapid respiratory pathogen 
testing at the POC with similar sensitivities and specificities as 



















Figure 5. Performance of the method for influenza B virus detection at the 
25-minute time point. The dashed line represents the cut-off value set for 
positive test result. 
When considering the treatment of influenza virus positive patients, 
the subtype information (influenza A or B) is of minor importance 
because of the similar treatment. Keeping this in mind, we developed a 
duplexed assay for rapid detection of influenza A and B viruses. The 
method applies microspheres specific for both the viruses and a 
combination of two separate tracers. The concomitant assay method is 
described in Appendix 3. 
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4.5 Detection of specific antibodies 
Applicability of the TPX technique for rapid serodiagnostic testing was 
studied and discussed in Publication III. Separation-free detection 
techniques do not allow conventional class-specific detection of 
specific antibodies. Instead, an alternative binding principle must be 
applied. 
The antibody-bridging (AB) binding principle provides an alternative 
means for serodiagnostic testing. An assay method for adenovirus-
specific antibodies was developed to prove the principle of this type of 
assay on the TPX platform (III). The response of the new AB method 
was compared to the response of a standard class-specific ELISA 
method. This study revealed that the new method allows detection of 
Immunoglobulin G and A class adenovirus (hexon antigen) -specific 
serum antibodies, whereas the method was unable to detect IgM-
antibodies. IgM contributed to the signal response only when IgG was 
also present in high concentrations. The failure to detect IgM alone 
was accounted for by the inability of IgM antibodies to bind 
simultaneously solid-phase antigens and soluble tracer antigens (III). 
An interesting kinetic phenomenon was observed in the new assay 
method (III). For IgG-molecules, at low analyte concentrations, the 
maximum signal was reached within 60 minutes, after which the 
signals started to decrease (Figure 6). At higher concentrations, 
normal immunoassay kinetics was observed. We explained this 
phenomenon by bivalent irreversible binding of the antibodies onto the 
solid-phase antigens. At low analyte concentrations (reagent excess) 
immuno complexes can rearrange: an antibody molecule bound by one 
arm to the antigen-coated surface, and by the other arm to a labelled 
antigen (signal-giving complex), can reorganize to bind on the solid 
phase using both of its Fab arms. This leads to a release of the labelled 
antigen from the solid phase, and a decrease in fluorescence signal 
levels. The phenomenon does not lead to false negative results as the 
detection will be finished before the signals start to decline. 
If bivalent binding is to be avoided, then the surface antigen density 
has to be adjusted so that the average distance between two antigens on 
the surface is longer than the extent of the Fab arms. We did this by 
diluting the antigen density of the surface down to a 1/10 mass 
proportion using BSA as dilutant (unpublished results). This resulted 
in lower signal dynamics and poorer signal statistics that hampered 
data analysis. Thus, conclusions could not be made with respect to 
bivalent binding. Nor did this study enable detection of IgM-class 
antibodies, supporting our suggestion for the mechanism. 
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Conformational change of IgM molecules from planar to staple-like 
conformation can happen even as a result of single Fab-arm binding 
(III). We have also demonstrated that after initial incubation with the 
tracer antigen, the IgM is able to bind to the antigen surface 
(unpublished data by Hanna Smolander) but it still does not give an 
antibody-bridging signal. Binding of the IgM to the antigen surface 
thus seems to lead to an instant dissociation of the labelled antigen. In 
the literature, IgM has been shown to give good signal response in 
antibody-bridging methods for other pathogens. This suggests that this 
phenomenon is antigen dependent and might have to do with the size 
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Figure 6. Signal kinetics of the antibody-bridging method at different analyte 
concentrations. Y-axis shows normalised signals (to the maximum signal of 
the respective reaction). The analyte concentration 2048 pM is at the hook of 
the dose-response curve. Measurement time points are shown on the right. 
Because dilution of the antigen surface density results in lower signal 
levels and lower sensitivity, the dilution strategy should not be applied 
in one-step antibody-bridging methods. This is in line with the 
literature. It has been shown that in one-step incubation methods (in 
heterogeneous assay systems) the optimization of antigen density is not 
as crucial as it is in two-step incubation methods (Bourdage 2005).  
In Publication III we reported that passive coating of the hexon 
antigen resulted in partial loss of functionality. This was seen as lower 
signals compared to the biotin-avidin strategy. This finding was 
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prominent, especially when monoclonal antibodies were used as 
analytes. In the assay of clinical samples, however, the passive coating 
strategy provided good results. This is most probably connected with 
the polyclonal nature of serum antibodies. 
The antibody-bridging principle does not allow determination of the 
infection status (primary, secondary, or past) as the class-specific 
methods do. To overcome this limitation, we proposed combining the 
antibody-bridging technique with the avidity index technique (III). 
This combination should enable separation-free serodiagnostic testing, 
which would also provide information about infection status. 
4.6 On-line detection of microbial growth 
The possibility to apply the TPX technique to on-line monitoring of 
bacterial growth was studied in Publication V. The new methodology 
for monitoring bacterial growth is based on a combination of an 
immunometric assay principle and microbial culturing in closed assay 
reaction wells. We used Staphylococcus aureus as the model organism. 
When growth medium was used in place of a regular assay buffer, 
sample bacteria were able to grow. This resulted in increasing numbers 
of antigens, which were then sandwiched on the microspheres and 
detected. According to the results, the TPX technique allows on-line 
monitoring of species-specific growth. Increasing turbidity of the 
reaction mixture interfered with signal measurement but did not impair 
analysis of the results. 
To ensure that the immunoreagents do not affect the bacterial growth 
and distort the results, we studied the effect of the reagents on growth. 
No effect on growth was observed (V).  
The detection limits of the new method for whole bacterial cells were 
studied in both growth-inhibiting and growth-sustaining (after 6 hours 
of culturing) conditions. The detection sensitivities were strain-
dependent and were, on average, 5×105 and 3×104 colony forming 
units/ml, respectively. The new method recognized all seven tested S. 
aureus strains and cross-reacted (slightly) with only one out of seven 
coagulase negative staphylococcus strains, indicating good specificity. 
The new methodology could be used for several applications in 
microbiological research such as studies of cell respiration, 
cytotoxicity, and growth-inhibiting or growth-promoting substances. 
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4.7 Antimicrobial susceptibility testing 
In Publication V, we developed a new methodology for antimicrobial 
susceptibility testing. This took advantage of the recent discovery that 
the TPX technique allows on-line monitoring of species-specific 
growth. Again, S. aureus was chosen as proof-of-concept analyte. The 
method applied dried reagents. When the growth medium was 
supplemented with an antimicrobial agent the growth of the bacteria 
was inhibited proportionally to the susceptibility of the bacteria. Thus, 
the new method allowed determination of antimicrobial susceptibility 
by a single-step assay protocol. 
Correlation between the AST results of the new method and the 
conventional broth dilution method was studied with four oxacillin-
susceptible and three oxacillin-resistant strains. The new method 
correctly identified all susceptible and resistant strains, and the results 
correlated well with the minimum inhibitory concentration values of 
the reference method (V).  
To evaluate the performance of the TPX technique for direct sample 
analysis (without pure culture) the effect of competing growth was 
studied by growing S. aureus and S. epidermidis simultaneously in the 
reaction wells. We found that the monitoring of S. aureus specific 
growth was possible even when S. epidermidis was present in 350-fold 
excess compared to S. aureus (V). According to this result, the 




The dry-chemistry reagent concept and the nanoparticulate tracers 
developed in this thesis enabled the use of the TPX assay technique for 
rapid testing of infectious diseases in different application areas. 
Compared to current laboratory methods, the TPX methods are simple 
to perform and still they provide high performance. Due to the dried 
reagents and the separation-free fluorescence detection, the assay 
protocols are one-step. This is in contrast to many of the proposed 
POC techniques which must apply complicated test cartridges and 
liquid handling. 
The TPX assay technique uses coated microspheres as solid phase 
carriers for the immunoaffinity reactions. This makes quality control 
easy compared to the coated-tube techniques. The technique and the 
reagents showed robustness throughout the studies. Small reaction 
volumes, low reagent concentrations, and the microsphere solid-phase 
chemistry mean low manufacturing costs. Furthermore, compared to 
many of the POC techniques, the new technique provides higher 
sensitivity, and it gives quantitative test results in electronic format. In 
conclusion, the new technique seems to meet most of the desirable 
features of a POC immunoanalyser (von Lode 2005). 
Limitations of the technique include limited applicability to whole 
blood samples. This property would be of value when analyzing 
samples in emergency care. Nevertheless, analytes with high reference 
range (nM) can be analysed from whole blood upon sufficient dilution. 
Another limitation is the relatively long measurement time per reaction 
well (20−60 seconds). This is not a major limitation in POC testing but 
it may limit the applicability in centralized high-throughput testing. 
Unlike in ELISA, bioaffinity binding reagents in the TPX platform 
must be very pure and of high specific acitivity. This may pose 
challenges in the method development. Yet another drawback of the 
TPX technique is that the fluorescence reader is more complex in 
design, and thus more expensive, compared to the conventional 
photometrical detectors used in conventional ELISA methods. 
5.1 Dry-chemistry reagents 
Conventionally, immunoassay methods have used soluble assay 
reagents. Such reagents must be dispensed into the reaction chambers 
at the point of use, typically in a multistep mode with washes in 
between the steps. An alternative approach is to use dry-chemistry 
reagents – the analyte specific reagents are dispensed into the reaction 
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chambers or onto the test slide already during the manufacturing 
process of the test kits, followed by drying. Dried reagents markedly 
simplify test protocols, prolong the shelf-lives at room temperature, 
and make shipping of the test reagents easy. The use of dried reagents 
can be considered to be a prerequisite for POC testing and lab-on-a-
chip applications (II). Pre-dispensed reagents also mean better 
accuracy in reagent concentrations due to automated dispensing at the 
manufacturing facilities. 
Dried reagents have traditionally been applied in lateral flow tests but 
currently, also an increasing number of immunochemistry analysers 
use dried reagents. However, as long as the signal detection requires 
physical separation of the bound and unbound fractions, the test 
instruments must use complicated liquid handling. In other words, 
physical separation-steps mean complicated instrument design and 
high assay costs. 
The use of dried reagents is sometimes associated with compromised 
performance in comparison to corresponding soluble reagents. For 
example, drying may result in reduced functionality of binding 
reagents, and increased imprecision and non-specific binding. 
Sensitivity and precision are thereby compromised. These problems 
are usually minimized by including buffer additives and by physically 
separating the solid phase reagent and the tracer. Such problems were 
not encountered with the methods developed in this study (II, IV, V). 
In general, unspecific binding is seldom met in the TPX technique. 
This is most probably due to i) low reagent concentrations, ii) the 
quality of the used reagents, as otherwise the obtained sensitivities 
would not be possible, and iii) the relatively high level of background 
signal, which originates from the unbound fraction of the tracer (in nM 
concentration). In the TPX technique, the background signal is 
governed by the free fraction of the fluorescent tracer. Therefore, it is 
rather tolerant of unspecific binding. 
Surprisingly, also the influenza B virus method which applied 
nanoparticulate tracer showed the same performance with soluble and 
dried reagents. Non-specific binding was not observed either. Initial 
dry-chemistry reagent studies using the NPT method for CRP (I) 
suggested that the NPT and microsphere reagents sometimes aggregate 
in high analyte concentrations (unpublished results) requiring the use 
of physical separation. Because such problems were not encountered 
with the other methods, we concluded that the problems with the CRP 
reagents were related to the pentameric nature of the CRP molecule. 
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In conclusion, the developed dry-chemistry reagent methods showed 
good performance and robustness throughout the studies with different 
application types. The use of dried reagents with the separation-free 
TPX assay technique makes it well suited for POC applications. 
5.2 Multianalyte point-of-care testing of 
respiratory pathogens 
In the management of respiratory tract infections, physicians usually 
make the diagnosis on the basis of clinical findings, anamnesis, and 
epidemiologic picture. Sometimes, samples are taken after visiting the 
physician, and they are analysed for specific pathogens either with 
rapid POC tests or with laboratory methods. Thus, the patient may 
need to return to the physician for the final diagnosis. Rapid and cost-
effective multianalyte POC tests would enable reversing this mode of 
operation. Nursing stuff could be trained to recognize symptoms 
according to a standardized protocol (strategy already in use, 
Rautakorpi 2006b), followed by collection of appropriate specimen(s), 
and analysis of the sample(s) at the point-of-care. The test result would 
then be available for the physician when meeting the patient for the 
first time. According to this vision, a specific microbiological 
diagnosis can be given for most patient cases within the same patient 
visit (Linde 2001). Such an operation mode would allow rapid 
initiation of correct treatment, including virus-specific drugs, and is 
expected to reduce unnecessary use of antibiotics. So far, 
implementation of this approach has been hampered by lack of suitable 
diagnostic methods, which would allow multianalyte POC testing.  
Although authors of studies dealing with the over-prescription of 
antibiotics and antimicrobial resistant bacteria do not usually call for 
better in vitro diagnostic tests, they feel uncomfortable treating the 
patients empirically. Recently, the physicians and microbiologists have 
started asking suppliers about multianalyte antigen detection tests 
(Personal observation, ESPID 2008 congress, Graz, Austria). 
In terms of disease burden (incidence, deaths, and economic loss) 
influenza is one of the most severe infectious diseases in the developed 
world. Secondary bacterial complications of influenza are major health 
risks, and they could be reduced by more efficient use of antiviral 
treatments. However, if the clinical diagnostic accuracy for influenza is 
poor (no in vitro pathogen detection), also the reputation of the 
antiviral medication will deteriorate. (Linde 2001) For this reason, 
virus drug companies should promote rapid in vitro testing. 
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Public awareness is expected to affect the testing routines of clinical in 
vitro diagnostics in the near future. It is expected that, in the future, 
patients will actively ask for a specific diagnosis in order to avoid 
unnecessary broad spectrum antibiotics, and to allow correct 
medication with specific antiviral drugs. If the test prices are 
reasonable, symptomatic patients will be eager to adopt the new 
diagnostics (Billings 2006). 
Despite the widely acknowledged need for rapid multianalyte POC 
tests, no such methods are on the markets. There are several 
multianalyte test systems available, such as immunofluorescence, 
ELISA, and those based on nucleic acid amplification (NAA), but 
none of them is well suited for rapid POC testing due to their high cost 
structure and complicated assay protocols. Mere reagent cost, at 
present, of one multiplexed NAA test with 10–20 analytes is 
approximately 100 €, and typically a single analyte PCR test ordered 
from the lab costs 50–100 €. For these reasons, it seems probable that 
the NAA methods will remain as a research tool or as an alternative 
technique for those rare patient cases where high assay cost is 
acceptable.  
On the basis of Publication IV, the TPX assay technique seems to be 
well suited for rapid POC testing of RTI diseases. Taking advantage of 
the kinetic measurement option of the TPX technique, we were able to 
determine the sensitivities of the methods at various time points. 
According to the results, sensitivities of the new methods at the 15–20 
minute time point are comparable to lateral flow tests. Prolonged 
incubation (2 hours) and repeated measurement provide performance 
comparable to the state-of-the-art laboratory methods. The kinetic 
measurement option provides fast results without compromising the 
overall sensitivity. A limitation of the new technique is the need for 
sample pre-treatment with detergent buffer prior to analysis, that takes 
one minute. On the other hand, a similar step is also needed in any 
other current POC test. Because the TPX measurement technique relies 
on detection of individual microspheres by their scattering, clinical 
specimens should be obtained by using swabs made of artificial fibre 
(instead of cotton) that do not release particulate material. 
The challenge associated with the development of a multianalyte RTI 
test relates to the specimen collection and pre-treatment. The optimal 
specimen type depends on the pathogen species. In the clinical practice 
of a multianalyte test with high coverage of both viruses and bacteria, 
probably two swab specimens should be taken, one from the nose and 
one from the throat. These swabs would then be combined with 
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appropriate extraction reagents, followed by dilution and dispensing 
into the test cartridge. However, the sample pre-treatment poses 
another challenge as different pathogens may reguire different pre-
treatments for optimal sensitivity and specificity. 
Following the development of influenza A and B virus antigen 
detection methods (IV), we have studied the applicability of the TPX 
assay technique for multinalyte testing of RTIs in the described format. 
We have developed new methods for common respiratory tract 
pathogens including S. pyogenes, S. pneumoniae, respiratory syncytial 
virus, metapneumovirus, adenovirus, and parainfluenza viruses. The 
new methods show excellent sensitivity (90-100 %) and specificity 
(close to 100 %) compared to current rapid tests based on lateral flow 
(bacteria), or laboratory tests based on TR-FIA or ELISA (viruses). 
(Koskinen 2008a, Koskinen 2008b, Koskinen 2008c) By running the 
new assays in multianalyte format at the POC it would be possible to 
obtain the test results within the same patient visit. This would allow 
rapid and accurate pathogen-specific diagnoses. 
The manufacturing cost of the new multianalyte RTI test is expected to 
be close to those of the current single analyte rapid tests because of the 
simple assay procedures and low reagent consumption. A further 
advantage of the new technique is that the same instrument can be used 
for the measurement of systemic infection markers such as C-reactive 
protein (CRP) (I), thus complementing the analyte portfolio. 
Currently, multianalyte detection methods are often developed by 
multiplexing several reactions into a one reaction vessel. Multiplexing 
is known to be difficult, and it results in compromised assay 
performance. We studied multiplexing by combining the influenza A 
and B virus antigen detection methods (IV) into one reaction 
(Appendix 3). This duplexed method showed good performance in 
relation to the reference methods on DELFIATM, but sensitivity was 
compromised in comparison to the corresponding single analyte 
methods. Most probably, further multiplexing would further decrease 
assay sensitivity. The multianalyte testing on the TPX platform would 
not be realized by multiplexing, but instead, by running separate tests 
in parallel assay wells. This multianalyte approach meets the goals of 
multiplexing, but returns an uncompromised detection performance. 
Since the TPX detection technique relies on microscopic optical 
detection, the performance of the technique is independent of the assay 
volume. This property makes TPX a suitable detection technique for 
miniaturized assay formats, such as “Lab-on-a-Chip” formats (II). The 
combination of the TPX technique and miniaturized assay chips would 
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allow the design of disposable multianalyte testing cartridges for POC 
testing. Multianalyte assays could be brought about, as described 
above, by having several parallel reaction wells or by multiplexing 
several reactions to a single reaction cuvette. Multianalyte tests using 
the TPX technique can be designed for different disease types and 
screening applications, e.g. a cartridge for respiratory infections (IV) 
or for pathogen-specific antibodies (III). The exact composition of the 
reagents in the cartridge could be easily modified, for example, 
according to market region, prevailing infectious agents within a 
population, or the needs of a laboratory. 
The multianalyte infectious diseases test could also be used for real-
time epidemiological surveillance. In contrast to conventional rapid 
assays, the TPX technique is characterized by an automated results 
read-out. Thus, the analysers could be connected via the Internet to a 
global database and surveillance system allowing health-care 
authorities to monitor ongoing infections on-line. Such a surveillance 
system would support the control over infectious diseases and 
epidemics, and provide an “early warning” system for changes in 
pathogen activities (Linde 2001, OECD, WHO 2005). Such 
multianalyte testing would have a high impact, for both the individual 
and for society. 
5.3 Antibody bridging − avidity index technique 
For decades serodiagnostic testing has been based on the use of class-
specific methodology and paired serum analysis. Limitations of the 
class-specific methods were discussed in Section 1.4.2. Because of the 
slowness of the immunoresponse and the time lag of paired serum 
analysis, rapid POC testing does not usually provide added value in 
comparison to conventional centralised laboratory serology. 
Furthermore, class-specific detection can not be realized by separation-
free techniques that would be adaptable for POC testing. 
In recent years, method specificity (Valdes 1992) and matrix 
interferences (Kricka 1999, Selby 1999, Levinson 2002) have gained 
wide publicity. This is highlighted, for example, by a recent Editorial 
(Bjerner 2005) and an Opinion (Ismail 2005) in the Clinical Chemistry 
journal. In order to improve the accuracy of clinical immuno-
diagnostics, alternative methodologies should be developed. The field 
of serodiagnostic techniques, however, has shown relatively little 
research activity in the last few decades. 
One strategy for reduction of sample interferences in class-specific 
methods is to remove the interfering substances. This, however, is 
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tedious and markedly increases the turn-around-time of sample 
analysis. Other strategies include modification of anti-immunoglobulin 
reagents, and the use of appropriate buffer additives. (Bjerner 2005) 
An ideal strategy would be the use of an immunoassay scheme less 
prone to interferences. Therefore, the serological methodology 
alternative to class-specific detection has been developed. 
An alternative approach to the use of anti-immunoglobulins is the 
antibody-bridging (AB) assay scheme. In this approach, only antigens 
are used as reagents, both in the solid-phase and as tracer. 
Theoretically, this approach is the only one that allows separation-free 
detection of specific antibodies. The principle has several advantages: 
(i) It has been demonstrated both theoretically and experimentally 
(Siitari 1990, Bürgisser 1996, Ankelo 2003, Westerlund-Karlsson 
2003) that assay methods following the principle are free from 
interference caused by rheumatoid factors, heterophilic antibodies 
and the complement, which frequently cause problems in assays 
based on anti-immunoglobulin antibodies. This is because the 
assay principle does not employ anti-immunoglobulin reagents. 
(ii) In contrast to conventional class-specific methods, AB methods 
are free from bias caused by differences in the affinities of anti-
immunoglobulin reagents. 
(iii) In the AB assay, the analyte has to bind to two or more antigens to 
contribute to the final signal output. This leads to superior 
specificity compared to class-specific methods (Miyazawa 1988, 
Siitari 1990, Bürgisser 1996, Horimoto 1997, Miyazawa 1999). 
(iv) For the same reason, the principle effectively eliminates the signal 
originating from unspecific binding. This allows the use of low 
sample dilutions (Chang 1984, Horimoto 1997, Miyazawa 1999, 
Ankelo 2003, Westerlund-Karlsson 2003). 
(v) The signal output of the assay principle is proportional to the 
number of labelled antigens bound on the analyte antibody. The 
assay principle may thus provide superior sensitivity for 
multivalent IgM-class antibodies. This leads to earlier detection of 
an immune response. This theory has also been demonstrated 
experimentally (Chang 1984, Gallarda 1992, Bürgisser 1996). 
(vi) The principle allows more convenient determination of specific 
antibodies from different species compared to class-specific 
methods (Kristiansen 1997). 
The advantages of the antibody-bridging principle are expected to 
provide improved diagnostic performance compared to classical 
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methods. Although the AB principle is widely applied in commercial 
serodiagnostic tests (e.g. on PrismTM, ElecsysTM, and Centaur® 
platforms), there are very few reports in the literature which describe 
methods based on this assay principle. None of the published reports 
describes a separation-free method; all of them rely on heterogeneous 
assay format with washing steps for specific signal generation. 
The proof-of-principle AB method for adenovirus specific antibodies 
showed good performance in comparison to class-specific ELISA 
(III). Interestingly, IgM-class antibodies did not give a signal response 
either when using the AB method on a TPX platform (III), or when 
using the AB on a DELFIATM platform (unpublished data). The same 
phenomenon has been reported in the literature (Aggerbeck 1996, 
Miyazawa 1988), although, in other studies AB has been shown to give 
a strong signal response for IgM-class antibodies (Chang 1984, 
Gallarda 1992, Bürgisser 1996). The aspects affecting the reactivity of 
IgM in AB methods need to be studied in more detail in the future. 
The main drawback of the AB principle is that it does not provide 
information about the immunoglobulin subclasses. Thus, it can not 
differentiate between primary and secondary infections. This limitation 
could be overcome by combining the AB principle with the avidity 
index technique (see III). The antibody-bridging principle and the 
avidity index methodology, in combination, could provide superior 
diagnostic performance compared to conventional techniques. This 
claim is based on the above-mentioned facts (see 1.4.2, and 5.3). The 
proposed technique combination: i) is less susceptible to matrix 
interferences, ii) has higher specificity, iii) is less influenced by 
unspecific binding, iv) is highly sensitive, and v) provides results from 
a single serum sample. 
If the hypothesis proves to be correct, the new methodology would 
provide added value to immunity testing and assessment of infection 
status and phase. Compared to the current practice (class-specific 
methods), the new methodology would speed up the diagnosis, as 
paired sample analysis would be avoided. A faster and more accurate 
diagnosis improves patient care and leads to faster clinical recovery. 
5.4 Antimicrobial susceptibility testing 
New approaches for antimicrobial susceptibility testing have been 
introduced in recent years. Although most of them are based on nucleic 
acid amplification, novel methodologies that rely on bacterial culturing 
are still required because of the constrains of the genetic methods. The 
new methods should be able to challenge the traditional phenotypical 
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methods. In Publication V, we provided proof-of-principle for the 
suitability of the TPX technique for on-line monitoring of bacterial 
growth and for AST. The new methodology could allow AST directly 
from clinical samples with significantly shorter turn-around-times (6−8 
hours) compared to conventional methods. 
The main drawback of the method presented in Publication V is the 
narrow dynamic range. Samples have to be appropriately diluted to 
bring the initial bacterial concentration below the detection limit. On 
the other hand, the higher the dilution, the longer time required for a 
positive result. In consequence, the methods must apply several sample 
dilutions. This lowers the throughput and increases the assay cost. 
During the incubation, antibiotics disintegrate bacterial cells which 
results in an increase in the concentration of soluble antigens. This 
leads to a crawling up of the signal despite the fact that bacterial 
growth is inhibited. The phenomenon poses challenge for data analysis 
as pre-set cut-off values may not always give optimal results. 
The most time-taking step in current AST methods is the pure-
culturing step which is needed to eliminate other bacterial species. 
Susceptibility must be tested for one species at a time. Pure culture 
leads to loss of most of the diversity information of the population 
concerning antimicrobial resistance. In addition to acquisition of new 
infections, this might be one reason why several consecutive samples 
must sometimes be analysed before the patient is finally screened 
positive for MRSA. 
The new methodology tolerates other sample microbes rather well. 
This suggests that it could be used to analyse clinical samples without 
pure culture, thus maintaining the population diversity information. 
This should be a major advantage over the present methods. Before 
implementation for clinical diagnostics, the microbe-specific method 
should be further optimized with respect to antibodies (higher affinity, 
better recognition spectrum), selective growth medium, and 
atmospheric conditions. The re-optimised method should then be tested 
with clinical samples to reveal its true performance. 
The potential of the proposed new methodology is supported by the 
recent product launch by 3M (BacLite Rapid MRSA Test). The test 
takes advantage of a similar immunoassay approach. However, the two 
methodologies differ with respect to the detection technique; the 
method used by 3M applies a wash assay platform, whereas the TPX 
technique is wash-free. Other potential targets for rapid phenotypical 
AST would be S. pneumonia and Escherichia coli, for example. 
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6 Conclusions and prospective 
This study shows that the two-photon excitation assay technique in 
combination with dry-chemistry reagents is a versatile tool for rapid 
infectious diseases testing. The technique was shown to allow assays in 
the following application fields: i) general inflammation markers, ii) 
antigen detection, iii) serology, and iv) antimicrobial susceptibility 
testing. The platform allows one-step assay protocols that are a 
prerequisite for cost-effective and user-friendly point-of-care testing. 
The new technique can be considered a significant improvement over 
current rapid test methods. 
This study showed that the sensitivity of the TPX methods can be 
increased by using nanoparticulate tracers up to one to two orders of a 
magnitude. We also conclude that multianalyte detection is best 
realized by running the tests in parallel in separate assay wells. In those 
cases where relative amounts of two analytes in the sample are of 
clinical interest, multiplexing should be considered. 
Serological and microbial (AST) applications must be further studied 
in order to reveal their potential as tools for in vitro testing. In the near 
future, we aim to combine the antibody-bridging principle with the 
avidity index technique and evaluate the significance of this 
combination in clinical serodiagnostic testing. 
The most promising application field of the TPX assay technique is the 
rapid multianalyte testing of respiratory tract infections. Our future 
objective is to validate the multianalyte test in clinical settings. The 
described multianalyte test could be used in the “doctor’s office” as 
well as the in clinical laboratory, where it could replace current single 




Abed Y, Boivin G. Treatment of respiratory virus infections. Antiviral Res. 2006, 
70:1-16. Review. 
Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health 
Interview Survey, 1996. Vital Health Statistics, Series 10 (Hyattsville, Maryland, 
USA, National Center for Health Statistics, Centers for Diseases Control and 
Prevention). 1999. 
Aggerbeck H., Nørgaard-Pedersen, B. and Heron, I. Simultaneous quantitation of 
diphteria and tetanus antibodies by double antigen, time-resolved fluorescence 
immunoassay. J Immunol Methods. 1996, 190:171-83. 
Ahluwalia G, Embree J, McNicol P, Law B, Hammond GW. Comparison of 
nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory 
syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and 
enzyme-linked immunosorbent assay. J Clin Microbiol. 1987, 25:763-7. 
Allander T. Human bocavirus. J Clin Virol. 2008, 41:29-33. 
Allwinn R, Preiser W, Rabenau H, Buxbaum S, Sturmer M, Doerr HW. Laboratory 
diagnosis of influenza-virology or serology? Med Microbiol Immunol. 2002, 
191:157-60. 
Andersson A, Vetter V, Kreutzer L, Bauer G. Avidities of IgG directed against viral 
capsid antigen or early antigen: useful markers for significant Epstein-Barr virus 
serology. J Med Virol. 1994, 43:238-44. 
Andre M, Schwan A, Odenholt I; Swedish Study Group on Antibiotic Use. The use 
of CRP tests in patients with respiratory tract infections in primary care in Sweden 
can be questioned. Scand J Infect Dis. 2004, 36:192-7. 
Andreotti PE, Ludwig GV, Peruski AH, Tuite JJ, Morse SS, Peruski LF Jr. 
Immunoassay of infectious agents. Biotechniques. 2003, 35:850-9. 
Angeles Marcos M, Camps M, Pumarola T, Antonio Martinez J, Martinez E, Mensa 
J, Garcia E, Peñarroja G, Dambrava P, Casas I, Jiménez de Anta MT, Torres A. The 
role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir 
Ther. 2006, 11:351-9. 
Ankelo M, Westerlund-Karlson A, Ilonen J, Knip M, Savola K, Kankaanpää P, 
Meriö L, Siitari H, Hinkkanen A. Time-resolved fluorometric assay for detection of 
autoantibodies to glutamic acid decarboxylase (GAD65). Clin Chem. 2003, 49:908-
15. 
Apple FS, Murakami MM, Christenson RH, Campbell JL, Miller CJ, Hock KG, Scott 
MG. Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta. 
2004, 345:123-7. 
Arola M, Ruuskanen O, Ziegler T, Mertsola J, Nanto-Salonen K, Putto-Laurila A, 
Viljanen MK, Halonen P. Clinical role of respiratory virus infection in acute otitis 
media. Pediatrics. 1990, 86:848-55.  
Aromaa A, Koskinen S. Terveys ja toimintakyky Suomessa, Terveys 2000 
tutkimuksen perustulokset (Health and functional capacity in Finland. Baseline 
Bibliography 
 57
results of the Health 2000 health examination survey). In Finnish in: Publications of 
the National Public Health Institute (Kansanterveyslaitos, Helsinki, Finland). 2002. 
Barenfanger J, Drake C, Leon N, Mueller T, Troutt T. Clinical and financial benefits 
of rapid detection of respiratory viruses: an outcomes study. J Clin Microbiol. 2000, 
38:2824-8. 
Batchelder K, Miller P. A change in the market-investing in diagnostics. Nat 
Biotechnol. 2006, 24:922-6. Review. 
Beadling C, Slifka MK. How do viral infections predispose patients to bacterial 
infections? Curr Opin Infect Dis. 2004, 17:185-91. Review. 
Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-
associated diarrhoea. Best Pract Res Clin Gastroenterol. 2004, 18:337-52. Review. 
Becker K, Pagnier I, Schuhen B, Wenzelburger F, Friedrich AW, Kipp F, Peters G, 
von Eiff C. Does nasal cocolonization by methicillin-resistant coagulase-negative 
staphylococci and methicillin-susceptible Staphylococcus aureus strains occur 
frequently enough to represent a risk of false-positive methicillin-resistant S. aureus 
determinations by molecular methods? J Clin Microbiol. 2006, 44:229-31. 
Billings PR. Three barriers to innovative diagnostics. Nat Biotechnol. 2006,24:917-8. 
Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of 
respiratory infections in an employed population. Chest. 2002, 122:603-11. 
Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH; Infectious 
Diseases Society of America. Practice guidelines for the diagnosis and management 
of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin 
Infect Dis. 2002, 35:113-25. 
Bjerner J, Bormer OP, Nustad K. The war on heterophilic antibody interference. Clin 
Chem. 2005, 51:9-11. 
Boersma WG, Holloway Y, Kuttschrütter H, Löwenberg A, Snijder JA, Koëter GH. 
Antigen detection in oropharyngeal secretions for rapid diagnosis of pneumococcal 
pneumonia. Eur J Clin Microbiol Infect Dis. 1993, 12:217-20. 
Bourdage JS, Lee TN, Taylor JM, Willey MB, Brandt JT, Konrad RJ. Effect of 
double antigen bridging immunoassay format on antigen coating concentration 
dependence and implications for designing immunogenicity assays for monoclonal 
antibodies. J Pharm Biomed Anal. 2005, 39:685-90. 
Bűrgisser P., Simon, F., Wernli, M., Wűst, T., Beya, M.-F. and Frei, P.C. Multicenter 
evaluation of new double-antigen sandwich enzyme immunoassay for measurement 
of anti-human immunodeficiency virus type 1 and type 2 antibodies. J Clin 
Microbiol. 1996, 34:634-7. 
Butler CC, Rollnick S, Pill R, Maggs-Rapport F, Stott N. Understanding the culture 
of prescribing: qualitative study of general practitioners' and patients' perceptions of 
antibiotics for sore throats. BMJ. 1998, 317:637-42.  
Butler JC, Crengle S, Cheek JE, Leach AJ, Lennon D, O'Brien KL, Santosham M. 




Carrat F, Tachet A, Rouzioux C, Housset B, Valleron AJ. Evaluation of clinical case 
definitions of influenza: detailed investigation of patients during the 1995-1996 
epidemic in France. Clin Infect Dis. 1999, 28:283-90. 
Chang H-C, Takashima I, Arikawa J, Hashimoto N. Biotin-labeled antigen sandwich 
enzyme-linked immunosorbent assay (BLA-S-ELISA) for the detection of japanese 
encephalitis antibody in human and a variety of animal sera. J Immunol Methods. 
1984, 72:401-9. 
Clark TJ, McPherson PH, Buechler KF The triage cardiac panel. Point of Care. 2002, 
1:42-6. 
Clinica Reports. The Global Market for Viral Diagnostics 2004-2009.  
Coutinho P. www.pjbpubs.com/clinica_reports/viral.htm, Excecutive Summary, 
www.pjbpubs.com/uploads/RCgR802KRX258vpsHlyj.pdf (accessed 2/3/2008). 
2004. 
Covalciuc KA, Webb KH, Carlson CA. Comparison of four clinical specimen types 
for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) 
and cell culture methods. J Clin Microbiol. 1999, 37:3971-4. 
Datamonitor. Stakeholder Opinions: Respiratory syncytial virus (RSV) – A market 
yet to reach its full potential. Datamonitor report product code: DMHC2250. 2006. 
EDMA. European IVD market estimates 2003. European Diagnostics Manufacturers 
Association. www.edma-ivd.be. 2003. 
Eldan M, Leibovitz E, Piglansky L, Raiz S, Press J, Yagupsky P, Leiberman A, 
Dagan R. Predictive value of pneumococcal nasopharyngeal cultures for the 
assessment of nonresponsive acute otitis media in children. Pediatr Infect Dis J. 
2000, 19:298-303. 
Espinal MA, The global situation of MDR-TB. Tuberculosis. 2003, 83:44-51. 
Review. 
Fahey T, Smucny J, Becker L, Glazier R. Antibiotics for acute bronchitis. Cochrane 
Database of Systematic Reviews 2004, Issue 4. Art. No.: CD000245. DOI: 
10.1002/14651858.CD000245.pub2. 
Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised 
controlled trials comparing antibiotic with placebo for acute cough in adults. BMJ. 
1998, 316:906-10. 
Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 
2001, 32:675-85. 
Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-
influenza-related viral respiratory tract infection in the United States. Arch Intern 
Med. 2003, 163:487-94. 
Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, 
Goossens H; ESAC Project Group. European Surveillance of Antimicrobial 
Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother. 
2006, 58:401-7. 
File TM. Community-acquired pneumonia. Lancet. 2003, 362:1991-2001. Review. 
Bibliography 
 59
Fjaertoft G, Foucard T, Xu S, Venge P.Human neutrophil lipocalin (HNL) as a 
diagnostic tool in children with acute infections: a study of the kinetics. Acta 
Paediatr. 2005, 94:661-6. 
Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and 
respiratory syncytial virus. J Epidemiol Community Health. 2005, 59:586-90. 
Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in 
differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 
1230 children. Pediatr Infect Dis J. 2008, 27:95-9. 
Fluit AC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. 
Clin Microbiol Rev. 2001, 14:836-71. Review. 
Gallarda JL, Henrard DR, Liu D, Harrington S, Stramer SL, Valinsky JE, Wu P. 
Early detection of antibody to human immunodeficiency virus type 1 by using an 
antigen conjugate immunoassay correlates with the presence of immunoglobulin M 
antibody. J Clin Microbiol. 1992, 30:2379-84. 
GAVI Alliance. Global Alliance for Vaccines and Immunisation, Geneva, 
Switzerland, www.vaccinealliance.org/resources/2004_VFannual_en.pdf. 2004 
Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A 
streptococci. Clin Microbiol Rev. 2004, 17:571-80. Review. 
Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics for acute otitis media 
in children. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: 
CD000219. DOI: 10.1002/14651858.CD000219.pub2. 
Global Industry Analysts. Automated And Rapid Microbiological Tests - A Global 
Strategic Business Report, code MCP-1093, Global Industry Analysts, Inc. San Jose, 
California, USA. 
Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, 
upper respiratory tract infections, and bronchitis by ambulatory care physicians. 
JAMA. 1997, 278:901-4. 
Gonzales R, Barrett PH Jr, Crane LA, Steiner JF. Factors associated with antibiotic 
use for acute bronchitis. J Gen Intern Med. 1998, 13:541-8. 
Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute 
respiratory infections in the United States. Clin Infect Dis. 2001, 33:757-62. 
Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. 
Outpatient antibiotic use in Europe and association with resistance: a cross-national 
database study. Lancet. 2005, 365:579-87. 
Gould IM. The clinical significance of methicillin-resistant Staphylococcus aureus. J 
Hosp Infect. 2005, 61:277-82. Review. 
Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff 
HV. A modified enzyme-linked immunosorbent assay for measurement of antibody 
response to meningococcal C polysaccharide that correalate with baktericidal 
responses. Clin Diagn Lab Immunol. 1998, 5:479-85. 
Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. 
Lancet. 2000, 355:827-35. Review. 
Bibliography 
 60
Guerrant RL, Blackwood BL. Threats to global health and survival: the growing 
crises of tropical infectious diseases – our "unfinished agenda". Clin Infect Dis. 1999, 
28:966-86. 
Haber C. Microfluidics in commercial applications; an industry perspective. Lab 
Chip. 2006, 6:1118-21. 
Hamelin ME, Boivin G. Human metapneumovirus: a ubiquitous and long-standing 
respiratory pathogen. Pediatr Infect Dis J. 2005, 24(11 Suppl):S203-7. Review. 
Hänninen P, Soini A, Meltola N, Soini J, Soukka J, Soini E. A new microvolume 
technique for bioaffinity assays using two-photon excitation. Nat Biotechnol. 2000, 
18:548-50. 
Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with beta-
lactam resistance in Staphylococcus aureus. J Bacteriol. 1984, 158:513-6. 
Hedman K, Lappalainen M, Seppälä I, Mäkelä O. Recent primary toxoplasma 
infection indicated by a low avidity of specific IgG. J Infect Dis. 1989, 159:736-40. 
Hedman K, Vaheri A, Brummer-Korvenkontio M. Rapid diagnosis of hantavirus 
disease with an IgG-avidity assay. Lancet. 1991, 338:1353-6. 
Hedman K, Lappalainen M, Söderlund M, Hedman L. Avidity of IgG in 
serodiagnosis of infectious diseases. Rev Med Microbiol. 1993, 4:123-129. 
Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in 
the middle ear during acute otitis media. N Engl J Med. 1999, 340:260-4. 
Heikkinen T, Salmi AA, Ruuskanen O. Comparative study of nasopharyngeal 
aspirate and nasal swab specimens for detection of influenza. BMJ. 2001, 322:138. 
Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal swab versus nasopharyngeal 
aspirate for isolation of respiratory viruses. J Clin Microbiol. 2002, 40:4337-9. 
Heikkinen T, Järvinen A. The common cold. Lancet. 2003a, 361:51-9. Review. 
Heikkinen T, Chonmaitree T. Importance of respiratory viruses in acute otitis media. 
Clin Microbiol Rev. 2003b, 16:230-41. Review. 
Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, 
Kainulainen L, Puhakka T, Jartti T, Toikka P, Lehtinen P, Routi T, Juven T. Burden 
of influenza in children in the community. J Infect Dis. 2004, 190:1369-73. 
Heikkinen T, Osterback R, Peltola V, Jartti T, Vainionpää R. Human 
metapneumovirus infections in children. Emerg Infect Dis. 2008, 14:101-6. 
Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, 
Kallinen S, Stén M, Tarkiainen A, Rönnberg PR, Kleemola M, Mäkelä PH, Leinonen 
M. Etiology of childhood pneumonia: serologic results of a prospective, population-
based study. Pediatr Infect Dis J. 1998, 17:986-91. 
Hohenthal U, Vainionpää R, Meurman O, Vahtera A, Katiskalahti T, Nikoskelainen 
J, Kotilainen P. Aetiological diagnosis of community acquired pneumonia: Utility of 
rapid microbiological methods with respect to disease severity. Scand J Infect Dis. 
2008, 40:131-8. 
Honkanen PO, Rautakorpi UM, Huovinen P, Klaukka T, Palva E, Roine R, 
Sarkkinen H, Varonen H, Mäkelä M; MIKSTRA Collaborative Study Group. 
Bibliography 
 61
Diagnostic tools in respiratory tract infections: use and comparison with Finnish 
guidelines. Scand J Infect Dis. 2002, 34:827-30. 
Horimoto T, Takahashi H, Sakaguchi M, Horikoshi K, Iritani S, Kazamatsuri H, 
Ikeda K, Tashiro MA. Reverse-type sandwich enzyme-linked immunosorbent assay 
for detecting antibodies to borna disease virus. J Clin Microbiol. 1997, 35:1661-6. 
Hopstaken RM, Stobberingh EE, Knottnerus JA, Muris JW, Nelemans P, Rinkens 
PE, Dinant GJ. Clinical items not helpful in differentiating viral from bacterial lower 
respiratory tract infections in general practice. J Clin Epidemiol. 2005, 58:175-83. 
Hueston WJ, Mainous AG 3rd, Dacus EN, Hopper JE. Does acute bronchitis really 
exist? A reconceptualization of acute viral respiratory infections. J Fam Pract. 2000, 
49:401-6. 
Huhtinen P, Kivelä M, Kuronen O, Hagren V, Takalo H, Tenhu H, Lövgren T, 
Härmä H. Synthesis, characterization, and application of Eu(III), Tb(III), Sm(III), 
and Dy(III) lanthanide chelate nanoparticle labels. Anal Chem. 2005, 77:2643-8. 
Huletsky A, Giroux R, Rossbach V, Gagnon M, Vaillancourt M, Bernier M, Gagnon 
F, Truchon K, Bastien M, Picard FJ, van Belkum A, Ouellette M, Roy PH, Bergeron 
MG. New real-time PCR assay for rapid detection of methicillin-resistant 
Staphylococcus aureus directly from specimens containing a mixture of 
staphylococci. J Clin Microbiol. 2004, 42:1875-84. 
Hyvärinen J, Huovinen P, Järvinen H, Kotilainen P. Multiresistance in 
Staphylococcus spp. blood isolates in Finland with special reference to the 
distribution of the mecA gene among the Staphylococcus epidermidis isolates. The 
Finnish Study Group for Antimicrobial Resistance. APMIS. 1995, 103:885-91. 
Ieven M, Goossens H. Relevance of nucleic acid amplification techniques for 
diagnosis of respiratory tract infections in the clinical laboratory. Clinical 
Microbiology Reviews. 1997, 10:242-56. 
Ipp M, Carson S, Petric M, Parkin PC. Rapid painless diagnosis of viral respiratory 
infection. Arch Dis Child. 2002, 86:372-3. 
Ismail AA. A radical approach is needed to eliminate interference from endogenous 
antibodies in immunoassays. Clin Chem. 2005, 51:25-6. 
Jartti T, Lehtinen P, Vuorinen T, Österback R, van den Hoogen B, Osterhaus AD, 
Ruuskanen O. Respiratory picornaviruses and respiratory syncytial virus as causative 
agents of acute expiratory wheezing in children. Emerg Infect Dis. 2004, 10:1095-
101. 
Johnston SL, Sanderson G, Pattemore PK, Smith S, Bardin PG, Bruce CB, Lambden 
PR, Tyrrell DA, Holgate ST. Use of polymerase chain reaction for diagnosis of 
picornavirus infection in subjects with and without respiratory symptoms. J Clin 
Microbiol. 1993, 31:111-7. 
Jussila M, Sintonen H, Koivula I, Lumio J. Hengitystieinfektioiden hoito 
Terveyskeskuksessa – potilaan, lääkärin ja yhteiskunnan näkökulma (The Treatment 
of respiratory tract infections in primary health care: on the view of the patient, the 
doctor, and the society), article in Finnish with English Summary. Suomen 
Lääkärilehti. 2005, 60:2577-2582. 
Bibliography 
 62
Kaiser L, Lew D, Hirschel B, Auckenthaler R, Morabia A, Heald A, Benedict P, 
Terrier F, Wunderli W, Matter L, Germann D, Voegeli J, Stalder H. Effects of 
antibiotic treatment in the subset of common-cold patients who have bacteria in 
nasopharyngeal secretions. Lancet. 1996, 347:1507-10. 
Kartalov EP. Multiplexed microfluidic immunoassays for point-of-care in vitro 
diagnostics. Medical device link. September 2006. Accessed 9/14/2006. 
www.devicelink.com/ivdt/archive/06/09/009.html. 
Korppi M. Non-specific host response markers in the differentiation between 
pneumococcal and viral pneumonia: what is the most accurate combination? Pediatr 
Int. 2004, 46:545-50. 
Korhonen MH, Brunstein J, Haario H, Katnikov A, Rescaldani R, Hedman K. A new 
method with general diagnostic utility for the calculation of immunoglobulin G 
avidity. Clin Diagn Lab Immunol. 1999, 6:725-8. 
Koskinen JO, Laitinen I, Luotola J, Lilius, E-M, Soini J, Waris M. Seasonal variation 
of CRP studied by a separation-free microvolume ArcDiaTM TPX-assay technology. 
EuroMedLab 2003, 1-5 June 2003, Barcelona, Spain. Abstract, Clin. Chem. Lab. 
Med. 41, S 275. Special supplement. 
Koskinen JO, Vaarno J, Meltola NJ, Soini JT, Hänninen PE, Luotola J, Waris ME, 
Soini AE. Fluorescent nanoparticles as labels for immunometric assay of C-reactive 
protein using two-photon excitation assay technology. Anal Biochem. 2004, 328:210-
8. 
Koskinen JO, Vaarno J, Vainionpää R, Meltola NJ, Soini AE. A novel separation-
free assay technique for serum antibodies using antibody bridging assay principle and 
two-photon excitation fluorometry. J Immunol Methods. 2006, 309:11-24. 
Koskinen JO, Meltola NJ, Hänninen PE, Soini AE. Separation-free assay for thyroid-
stimulating hormone with femtomolar sensitivity. Euromedlab 2007, 3-7 June, 2007, 
Amsterdam, The Netherlands. Abstract, Clin. Chem. Lab. Med. 2007, 45, Special 
Supplement, pp S1-S473, abstract M228. 
Koskinen JO, Vainionpää R, Waris M, Huovinen P, Hedman K, Saukkoriipi A, and 
Soini AE. A New Rapid Method for Multianalyte POC Testing of Respiratory Tract 
Infections. Annual meeting and congress of the European Society for Clinical 
Virology 2008, Saariselkä, Finland, 12-15 March, 2008a. Oral presentation and 
abstract. 
Koskinen JO, Vainionpää R, Waris M, Huovinen P, Hedman K, Saukkoriipi A, 
Ruuskanen O, Ruohola A, Soini AE. Rapid Multianalyte Identification of 
Respiratory Tract Pathogens. 26th Annual ESPID Meeting, May 13-17, 2008b, Graz, 
Austria. Oral poster-walk presentation and abstract. 
Koskinen JO, Vainionpää R, Waris M, Huovinen P, Hedman K, Saukkoriipi A, 
Ruuskanen O, Ruohola A, Soini AE. Rapid multianalyte POC test to aid physicians 
in pathogen-specific diagnosis of respiratory infections. 25th Annual SSAC Meeting, 
September 18-21, 2008c, Copenhagen, Danmark. Oral presentation and abstract. 
Kotilainen P, Routamaa M, Peltonen R, Oksi J, Rintala E, Meurman O, Lehtonen 
OP, Eerola E, Salmenlinna S, Vuopio-Varkila J, Rossi T. Elimination of epidemic 
methicillin-resistant Staphylococcus aureus from a university hospital and district 
institutions, Finland. Emerg Infect Dis. 2003, 9:169-75. 
Bibliography 
 63
Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin 
Chem. 1999, 45:942-56. Review. 
Kristiansen M, Aggerbeck H, Heron I. Improved ELISA for determination of anti-
diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS. 1997, 105:843-53. 
Laihia JK, Koskinen JO, Waris ME, Jansén CT. Adaptation of the human skin by 
chronic solar-simulating UV irradiation prevents ultraviolet-B irradiation-induced 
rise in serum C-reactive protein levels. Photochem Photobiol. 2005, 81:654-8. 
Lehtinen P, Jartti T, Virkki R, Vuorinen T, Leinonen M, Peltola V, Ruohola A, 
Ruuskanen O. Bacterial coinfections in children with viral wheezing. Eur J Clin 
Microbiol Infect Dis. 2006, 25:463-9. 
Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone 
reduces recurrent wheezing after a first wheezing episode associated with rhinovirus 
infection or eczema. J Allergy Clin Immunol. 2007, 119:570-5. 
Lehtonen OP, Eerola E. The effect of different antibody affinities on ELISA 
absorbance and titer. J Immunol Methods. 1982, 54:233-40. 
Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) 
antibody interference with modern immunoassays. Clin Chim Acta. 2002, 325:1-15. 
Review. 
The Lewin Group. The Value of Diagnostics: Innovation, Adoption and Diffusion 
into Health Care. Washington DC. July 2005. Accessed 3/8/2008. 
www.advamed.org/NR/rdonlyres/61EB858F-EC9E-4FAB-9547-
09DABF7D2A72/0/thevalueofdiagnostics.pdf 
Linde A. The importance of specific virus diagnosis and monitoring for antiviral 
treatment. Antiviral Res. 2001, 51:81-94. Review. 
Livermore DM. Minimising antibiotic resistance. Lancet Infect Dis. 2005, 5:450-9. 
Review. 
von Lode P. Point-of-care immunotesting: approaching the analytical performance of 
central laboratory methods. Clin Biochem. 2005, 38:591-606. Review. 
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional 
burden of disease and risk factors, 2001: systematic analysis of population health 
data. Lancet. 2006, 367:1747-57. 
MacDonald RA, Hosking CS, Jones CL. The measurement of relative antibody 
affinity by ELISA using thiocyanate elution. J Immunol Methods. 1988, 106:191-4. 
Macfarlane P, Denham J, Assous J, Hughes C. RSV testing in bronchiolitis: which 
nasal sampling method is best? Arch Dis Child. 2005, 90:634-5. 
Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, 
Blomqvist S, Hyypiä T, Arstila P. Viruses and bacteria in the etiology of the 
common cold. J Clin Microbiol. 1998, 36:539-42. 
Madeley CR. Are point-of-care (POC) virological tests what is needed? Clin 
Microbiol Infect. 2007, 13:655-6. 
Meltola NJ, Wahlroos R, Soini AE. Hydrophilic labeling reagents of 
dipyrrylmethene-BF2 dyes for two-photon excited fluorometry: syntheses and 
photophysical characterization. J Fluoresc. 2004, 14:635-47. 
Bibliography 
 64
Meltola NJ, Kettunen MJ, Soini AE. Dipyrrylmetheneboron difluorides as labels in 
two-photon excited fluorometry. Part I-immunometric assays. J Fluoresc. 2005a, 
15:221-32. 
Meltola N J, Vaarno J, Soini AE. Dipyrrylmetheneboron difluorides as labels in two-
photon excited fluorometry. Part II-Nucleic acid hybridization assays. J Fluoresc. 
2005b, 15:233-242. 
Meltola N. Dipyrrylmetheneboron difluorides as labels in two-photon excited 
fluorometry. Ser. A1, Tom. 339, Annales Universitatis Turkuensis. 2005c. 
Meurman O. Detection of antiviral IgM antibodies and its problems-a review. Curr 
Top Microbiol Immunol. 1983, 104:101-31. Review. 
Miyazawa H., Inouye, S., Sakaguchi, M. and Koizumi, K. A reverse-sandwich 
ELISA for IgG antibody to a pollen allergen. J Allergy Clin Immunol. 1988, 82:407-
13. 
Miyazawa H, Bannai H, Yanase T, Morita C, Satoh S, Sugiyama J, Taniguchi S, 
Inouye S. A reverse-sandwich enzyme-linked immunosorbent assay for 
verocytotoxin 1 and 2 antibodies in human and bovine sera. Clin Diagn Lab 
Immunol. 1999, 6:701-4. 
Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and 
symptoms predicting influenza infection. Arch Intern Med. 2000, 160:3243-7. 
Monto AS. The seasonality of rhinovirus infections and its implications for clinical 
recognition. Clin Ther. 2002, 24:1987-97. Review. 
Monto AS. Occurrence of respiratory virus: time, place and person. Pediatr Infect 
Dis J. 2004, 23(1 Suppl):S58-64. Review. 
Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging 
infectious diseases. Nature. 2004, 430:242-9. Review. 
Needham CA, McPherson KA, Webb KH. Streptococcal pharyngitis: impact of a 
high-sensitivity antigen test on physician outcome. J Clin Microbiol. 1998, 36:3468-
73. 
Niesters HG. Molecular and diagnostic clinical virology in real time. Clin Microbiol 
Infect. 2004, 10:5-11. Review. 
Nohynek H, Valkeila E, Leinonen M, Eskola J. Erythrocyte sedimentation rate, white 
blood cell count and serum C-reactive protein in assessing etiologic diagnosis of 
acute lower respiratory infections in children. Pediatr Infect Dis J. 1995, 14:484-90. 
Nokso-Koivisto J, Kinnari TJ, Lindahl P, Hovi T, Pitkäranta A. Human picornavirus 
and coronavirus RNA in nasopharynx of children without concurrent respiratory 
symptoms. J Med Virol. 2002, 66:417-20. 
Noyola DE, Demmler GJ. Effect of rapid diagnosis on management of influenza A 
infections. Pediatr Infect Dis J. 2000, 19:303-7. 
Nuutila J, Hohenthal U, Laitinen I, Kotilainen P, Rajamäki A, Nikoskelainen J, Lilius 
EM. Quantitative analysis of complement receptors, CR1 (CD35) and CR3 (CD11b), 
on neutrophils improves distinction between bacterial and viral infections in febrile 




Nuutila J, Lilius EM. Distinction between bacterial and viral infections. Curr Opin 
Infect Dis. 2007, 20:304-10. Review. 
Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children 
with colds, upper respiratory tract infections, and bronchitis. JAMA. 1998, 279:875-7. 
OECD. OECD report: Biotechnology and ustainability, the fight against infectious 
disease. 2003. www.oecd.org/dataoecd/23/23/2508407.pdf 
O’Farrel B and Bauer J. Developing highly sensitive, more-reproducible lateral-flow 
assays. Part 1: New approaches to old problems. Medical device link. June 2006. 
www.devicelink.com/ivdt/archive/06/06/010.html (accessed 9/14/2006). 
O’Farrel B and Bauer J. Developing highly sensitive, more-reproducible lateral-flow 
assays. Part 2: New challenges with new approaches. Medical device link. July 2006. 
www.devicelink.com/ivdt/archive/06/07/011.html (accessed 9/14/2006). 
Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, Fouchier RA. 
Global patterns of influenza a virus in wild birds. Science. 2006, 312:384-8. Review. 
Orr PH, Scherer K, Macdonald A, Moffatt ME. Randomized placebo-controlled trials 
of antibiotics for acute bronchitis: a critical review of the literature. J Fam Pract. 
1993, 36:507-12. Review. 
Parkin DM. The global health burden of infection-associated cancers in the year 
2002. Int J Cancer. 2006, 118:3030-44. 
Peiris JSM, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory 
syndrome. N Engl J Med. 2003, 349:2431-41. Review. 
Peleg AY, Paterson DL. Modifying antibiotic prescribing in primary care. Clin Infect 
Dis. 2006, 42:1231-3. 
Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to 
secondary bacterial pneumonia. J Infect Dis. 2005a, 192:249-57. 
Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T. Accuracy of clinical 
diagnosis of influenza in outpatient children. Clin Infect Dis. 2005b, 41:1198-200. 
Peltola V, Waris M, Hyypiä T, Ruuskanen O. Respiratory viruses in children with 
invasive pneumococcal disease. Clin Infect Dis. 2006a, 43:266-8. 
Peltola V, Mertsola J, Ruuskanen O. Comparison of total white blood cell count and 
serum C-reactive protein levels in confirmed bacterial and viral infections. J. Pediatr. 
2006b, 149:721-724. 
Perkins MD, Small PM. Partnering for better microbial diagnostics. Nat Biotechnol. 
2006, 24:919-21. 
Pirhonen I, Husman T, Pekkarinen J. Työikäisen väestön hengitystieinfektioiden 
yleisyys, lääkärissäkäynnit ja sairauspoissaolot. Suom Lääkäril. 1994, 49:2538-44. 
Article in Finnish. 
Pitkäranta A, Hayden FG. Rhinoviruses: important respiratory pathogens. Ann Med. 
1998, 30:529-37. Review. 
Pray LA. Infectious diseases: R&D challenges and market drivers. Advances reports. 
2006. www.advancesreports.com. Executive summary. 
Bibliography 
 66
Puhakka T, Mäkelä MJ, Alanen A, Kallio T, Korsoff L, Arstila P, Leinonen M, 
Pulkkinen M, Suonpää J, Mertsola J, Ruuskanen O. Sinusitis in the common cold. J 
Allergy Clin Immunol. 1998b, 102:403-8. 
Pullen G.R., Fitzgerald, M.G. and Hosking, C.S. Antibody avidity determination by 
ELISA using thiocyanate elution. J Immunol Methods. 1986, 86:83-7. 
Putto A. Febrile exudative tonsillitis:viral or streptococcal? Pediatrics. 1987,80:6-12. 
Rautakorpi UM, Huikko S, Honkanen P, Klaukka T, Makela M, Palva E, Roine R, 
Sarkkinen H, Varonen H, Huovinen P; MIKSTRA Collaborative Study Group. The 
Antimicrobial Treatment Strategies (MIKSTRA) program: a 5-year follow-up of 
infection-specific antibiotic use in primary health care and the effect of 
implementation of treatment guidelines. Clin Infect Dis. 2006a, 42:1221-30. 
Rautakorpi UM. Common infections in Finnish primary health care. Doctoral 
Dissertation, Acta Universitatis Tamperensis 1137, University of Tampere, Tampere, 
Finland. 2006b. 
Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four 
automated high-sensitivity C-reactive protein methods: implications for clinical and 
epidemiological applications. Clin Chem. 2000, 46:461-8. 
Roque-Afonso AM, Grangeot-Keros L, Roquebert B, Desbois D, Poveda JD, 
Mackiewicz V, Dussaix E. Diagnostic relevance of immunoglobulin G avidity for 
hepatitis A virus. J Clin Microbiol. 2004, 42:5121-4. 
Roth SB, Jalava J, Ruuskanen O, Ruohola A, Nikkari S. Use of an oligonucleotide 
array for laboratory diagnosis of bacteria responsible for acute upper respiratory 
infections. J Clin Microbiol. 2004, 42:4268-74. 
Rubin MA, Bateman K, Alder S, Donnelly S, Stoddard GJ, Samore MH. A 
multifaceted intervention to improve antimicrobial prescribing for upper respiratory 
tract infections in a small rural community. Clin Infect Dis. 2005, 40:546-53. 
Ruohola A, Meurman O, Nikkari S, Skottman T, Salmi A, Waris M, Osterback R, 
Eerola E, Allander T, Niesters H, Heikkinen T, Ruuskanen O. Microbiology of acute 
otitis media in children with tympanostomy tubes: prevalences of bacteria and 
viruses. Clin Infect Dis. 2006, 43:1417-22. 
Samuels M. Viruses and sudden infant death. Paediatr Respir Rev. 2003, 4:178-83. 
Review. 
Savolainen C, Blomqvist S, Hovi T. Human rhinoviruses. Paediatr Respir Rev. 2003, 
4:91-8. Review. 
Schultze D, Thomas Y, Wunderli W. Evaluation of an optical immunoassay for the 
rapid detection of influenza A and B viral antigens. Eur J Clin Microbiol Infect Dis. 
2001, 20:280-3. 
Selby C. Interference in immunoassay. Ann Clin Biochem. 1999, 36:704-21. Review. 
Siitari H, Turunen P, Schrimsher J, Nunn M. New sensitive and specific assay for 
human immunodeficiency virus antibodies using labeled recombinant fusion protein 
and time-resolved fluoroimmunoassay. J Clin Microbiol. 1990, 28:2022-9. 
Bibliography 
 67
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-
reactive protein levels as markers of bacterial infection: a systematic review and 
meta-analysis. Clin Infect Dis. 2004, 39:206-17. 
Sintchenko V, Gilbert GL, Coiera E, Dwyer D. Treat or test first? Decision analysis 
of empirical antiviral treatment of influenza virus infection versus treatment based on 
rapid test results. J Clin Virol. 2002, 25:15-21. 
Soilu-Hänninen M, Koskinen JO, Laaksonen M, Hänninen A, Lilius EM, Waris M. 
High sensitivity measurement of CRP and disease progression in multiple sclerosis. 
Neurology. 2005, 65:153-5. 
Soini JT, Soukka JM, Meltola NJ, Soini AE, Soini E, and Hänninen PE. Ultra 
sensitive bioaffinity assay for micro volumes. Single Molecules. 2000, 1:203-6. 
Soini JT. Development of instrumentation for single-step, multiplexed, microvolume 
bioaffinity assays. Doctoral Dissertation, Annales Universitatis Turkuensis A1:281, 
Turun yliopisto, Turku, Finland. 2002a. 
Soini JT, Soukka JM, Soini E, Hänninen PE. Two-photon excitation 
microfluorometer for multiplexed single-step bioaffinity assays. Rev of Sci Instrum. 
2002b, 73:2680-5. 
Soukka, T. Immunoassay designs and potential of particulate photoluminescent 
lanthanide reporters. Annales Universitatis Turkuensis A1:304, Turun yliopisto, 
Turku, Finland. 2003. 
Steinke D, Davey P. Association between antibiotic resistance and community 
prescribing: a critical review of bias and confounding in published studies. Clin 
Infect Dis. 2001, 33 Suppl 3:S193-205. Review. 
Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological 
balance of human microflora. Lancet Infect Dis. 2001, 1:101-14. Review. 
Sundsfjord A, Simonsen GS, Haldorsen BC, Haaheim H, Hjelmevoll SO, Littauer P, 
Dahl KH. Genetic methods for detection of antimicrobial resistance. APMIS. 2004, 
112:815-37. Review. 
Syrjänen RK, Herva EE, Mäkelä PH, Puhakka HJ, Auranen KJ, Takala AK, Kilpi 
TM. The value of nasopharyngeal culture in predicting the etiology of acute otitis 
media in children less than two years of age. Pediatr Infect Dis J. 2006, 25:1032-6. 
Thomas HIJ, Morgan-Capner P. Rubella-specific IgG1 avidity: a comparison of 
methods. J Virol Methods. 1991, 31:219-28. 
Thomas HIJ, Barret E, Hesketh LM, Wynne A, Morgan-Capner P. Simultaneous IgM 
reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella 
infection. J Clin Virol. 1999, 14:107-18. 
Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda 
K. Mortality associated with influenza and respiratory syncytial virus in the United 
States. JAMA. 2003, 289:179-86. 
Tirri ME, Huttunen RJ, Toivonen J, Härkönen PL, Soini JT, Hänninen PE. Two-
photon excitation in fluorescence polarisation receptor-ligand binding assay. J 
Biomol Screen. 2005, 10:314-9. 
Bibliography 
 68
Vaarno J, Meltola NJ, Soini AE, Soini JT. Separation-free microvolume assay of 
thyroxine (T4). Euromedlab 2003, June 1-5.2003. Abstract, Clin. Chem. Lab. Med. 
2003, Special supplement. 41: S 119. 
Vaarno J, Ylikoski E, Meltola NJ, Soini JT, Hänninen PE, Lahesmaa R, and Soini 
AE. New separation-free assay technique for SNPs by two-photon excitation 
fluorometry. Nucleic Acids Res. 2004, 32:e108. 
Valdes R Jr, Miller JJ. Increasing the specificity of immunoassays. J Clin 
Immunoassay. 1992, 15:87-96. 
van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of 
C-reactive protein in infections of the lower respiratory tract: systematic review. 
BMJ. 2005, 331:26. Review. 
van Gageldonk-Lafeber AB, Heijnen ML, Bartelds AI, Peters MF, van der Plas SM, 
Wilbrink B. A case-control study of acute respiratory tract infection in general 
practice patients in The Netherlands. Clin Infect Dis. 2005, 41:490-7. 
van Leeuwen WB, van Pelt C, Luijendijk A, Verbrugh HA, Goessens WH. Rapid 
detection of methicillin resistance in Staphylococcus aureus isolates by the MRSA-
screen latex agglutination test. J Clin Microbiol. 1999, 37:3029-30. 
Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. 
Antibiotic use in relation to the risk of breast cancer. JAMA. 2004, 291:827-35. 
Vernet G. Molecular diagnostics in virology. J Clin Virol. 2004, 31:239-47. 
Waris ME, Meltola NJ, Soini JT, Soini E, Peltola OJ, Hänninen PE. Two-photon 
excitation fluorometric measurement of homogeneous microparticle immunoassay 
for C-reactive protein. Anal Biochem. 2002, 309:67-74. 
Waris ME, Koskinen JO, Simell O, Knip M, Ilonen J. Onset of beta-cell 
autoimmunity is not associated with elevated concentration of C-reactive protein in 
children at genetic risk for Type 1 diabetes. Diabet Med. 2005, 22:1123-4. 
Waris ME, Heikkinen T, Osterback R, Jartti T, Ruuskanen O. Nasal swabs for 
detection of respiratory syncytial virus RNA. Arch Dis Child. 2007, 92:1046-7. 
Wellems TE, Miller LH. Two worlds of malaria. N Engl J Med. 2003, 349:1496-8. 
Westerlund-Karlsson A, Suonpaa K, Ankelo M, Ilonen J, Knip M, Hinkkanen AE. 
Detection of autoantibodies to protein tyrosine phosphatase-like protein IA-2 with a 
novel time-resolved fluorimetric assay. Clin Chem. 2003, 49:916-23. 
Wheat PF. History and development of antimicrobial susceptibility testing 
methodology. J Antimicrob Chemother. 2001, 48: 1-4. 
Whelen AC, Persing DH. The role of nucleic acid amplification and detection in the 
clinical microbiology laboratory. Annu Rev Microbiol. 1996, 50:349-73. Review. 
Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, 
Ward P. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 
2001, 20:127-33. 
WHO. World Health Organization Report on Infectious Diseases 2000, Overcoming 




WHO. Model Prescribing Information 2001. Drugs used in bacterial infections. 
World Health Organization, Geneva. 2001. 
http://whqlibdoc.who.int/hq/2001/9241401079.pdf 
WHO. The World Health Report 2004. World Health Organization, Geneva. 2004. 
www.who.int/whr/en/ 
WHO. WHO recommendations on the use of rapid testing for influenza diagnosis. 
World Health Organization, Geneva. 2005. www.who.int/en/ 
Wichelhaus TA, Kern S, Schäfer V, Brade V, Hunfeld KP. Evaluation of modern 
agglutination tests for identification of methicillin-susceptible and methicillin-
resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999, 18:756-8. 
Wild D. The Immunoassay Handbook. Chapter 15, Gimzewski et al., 
Immunobiological Biosensors. Third edition. Elsevier Ltd. UK. 2005. 
Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide 
distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002, 
2:25-32. Review. 
Wise R, Hart T, Cars O, Streulens M, Helmuth R, Huovinen P, Sprenger M. 
Antimicrobial resistance. Is a major threat to public health. BMJ. 1998, 317:609-10. 
Woo PC, Chiu SS, Seto WH, Peiris M. Cost-effectiveness of rapid diagnosis of viral 
respiratory tract infections in pediatric patients. J Clin Microbiol. 1997, 35:1579-81. 
Wu AH, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a point-
of-care assay for cardiac markers for patients suspected of acute myocardial 
infarction. Clin Chim Acta. 2004, 346:211-9. 
Xu SY, Pauksen K, Venge P. Serum measurements of human neutrophil lipocalin 
(HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab 
Invest. 1995, 55:125-31. 
Yager P, Edwards T, Fu E, Helton K, Nelson K, Tam MR, Weigl BH. Microfluidic 
diagnostic technologies for global public health. Nature. 2006, 442:412-8. Review. 
Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, 




Appendix 1: References for Table 1 
1. Juvén T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, Eskola J, Saikku 
P, Ruuskanen O. Etiology of community-acquired pneumonia in 254 hospitalized 
children. Pediatr Infect Dis J. 2000, 19:293-8. 
2. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute 
respiratory infections in the United States. Clin Infect Dis. 2001, 33:757-62. 
3. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, 
van der Heijden G, Verheij TJ; European Respiratory Society; European Society of 
Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult 
lower respiratory tract infections. Eur Respir J. 2005, 26:1138-80. Review. 
4. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and 
resistance patterns. Eur Respir J Suppl. 2002, 20:20-27. Review. 
5. Heikkinen T, Järvinen A. The common cold. Lancet. 2003a, 361:51-9. Review. 
6. Putto A. Febrile exudative tonsillitis:viral or streptococcal? Pediatrics. 1987,80:6-12. 
7. Heikkinen T, Chonmaitree T. Importance of respiratory viruses in acute otitis media. Clin 
Microbiol Rev. 2003b, 16:230-41. Review. 
8. Ruohola A, Meurman O, Nikkari S, Skottman T, Salmi A, Waris M, Osterback R, Eerola 
E, Allander T, Niesters H, Heikkinen T, Ruuskanen O. Microbiology of acute otitis media 
in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis. 
2006, 43:1417-22. 
9. Monto AS. The seasonality of rhinovirus infections and its implications for clinical 
recognition. Clin Ther. 2002, 24:1987-97. Review. 
Monto AS. Occurrence of respiratory virus: time, place and person. Pediatr Infect Dis J. 
2004, 23(1 Suppl):S58-64. Review. 
10. Puhakka T, Mäkelä MJ, Malmström K, Uhari M, Savolainen J, Terho EO, Pulkkinen M, 
Ruuskanen O. The common cold: effects of intranasal fluticasone propionate treatment. J 
Allergy Clin Immunol. 1998a, 101:726-31. 
11. Heikkinen T, Osterback R, Peltola V, Jartti T, Vainionpää R. Human metapneumovirus 
infections in children. Emerg Infect Dis. 2008, 14:101-6. 
12. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM, Young SA, 
Chambers ST, Murdoch DR. Incidence and characteristics of viral community-acquired 
pneumonia in adults. Thorax. 2008, 63:42-8. 
13. Puhakka T, Mäkelä MJ, Alanen A, Kallio T, Korsoff L, Arstila P, Leinonen M, Pulkkinen 
M, Suonpää J, Mertsola J, Ruuskanen O. Sinusitis in the common cold. J Allergy Clin 
Immunol. 1998b, 102:403-8. 
14. Hamelin ME, Boivin G. Human metapneumovirus: a ubiquitous and long-standing 
respiratory pathogen. Pediatr Infect Dis J. 2005, 24(11 Suppl):S203-7. Review. 
15. Angeles Marcos M, Camps M, Pumarola T, Antonio Martinez J, Martinez E, Mensa J, 
Garcia E, Peñarroja G, Dambrava P, Casas I, Jiménez de Anta MT, Torres A. The role of 
viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther. 2006, 
11:351-9. 
16. Arola M, Ruuskanen O, Ziegler T, Mertsola J, Nanto-Salonen K, Putto-Laurila A, 
Viljanen MK, Halonen P. Clinical role of respiratory virus infection in acute otitis media. 
Pediatrics. 1990, 86:848-55.  
17. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the 
middle ear during acute otitis media. N Engl J Med. 1999, 340:260-4. 
18. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, Blomqvist 
S, Hyypiä T, Arstila P. Viruses and bacteria in the etiology of the common cold. J Clin 
Microbiol. 1998, 36:539-42. 
Appendix 
 71
Appendix 2: Sensitive nanoparticulate 
tracer method for thyroid stimulating 
hormone 
Introduction and Experimental 
Some of the clinically important analytes, such as human thyroid 
stimulating hormone (hTSH) and cardiac markers, require very high 
detection sensitivities. To study the potential sensitivity of the TPX 
assay technique we chose to develop a nanoparticulate tracer (NPT) 
method for hTSH. This analyte has traditionally been used to reflect 
the sensitivity of new assay techniques. The preparation of NPT 
specific for hTSH was carried out as described in section 3.2. Antibody 
clone type optimization was needed for the method because the analyte 
requires extreme sensitivity and because of the chosen NPT approach. 
We also optimized the buffer composition for high sensitivity. 
Results and Discussion 
The optimized NPT method (50 000 microspheres per 20 µl reaction 
volume, NPT concentration 0.4 x 1013/L, assay buffer supplemented 
with 3 % PEG 6000) for hTSH was compared to a corresponding 
method applying molecular tracer (Figure 1). It turned out that 
different antibody clone pairs and configurations (solid-phase versus 
tracer) gave optimal performance depending on whether the method 
used either NPT (clone 5409 solid phase, clone 5405 tracer) or 
molecular tracer (MT, clone 5405 solid phase, clone 5404 tracer). The 
NPT method had lowest limit of detection (zero control + 3SD) in the 
reaction mixture of 0.01 mIU/L (20 femtomolar). The functional 
sensitivity, defined as the concentration co-efficient of variation ≤ 20 
%, was 0.05 mIU/L. Intra-assay imprecision at the concentration of 0.5 
mIU/L was 8 %. The corresponding values for the MT method were 
0.2 mIU/L, 0.5 mIU/L, and 20 %. The NPT method showed excellent 
linearity of the response (R2≥0.996). The NPT improved the detection 
sensitivity of the hTSH method by an order of magnitude. This 
sensitivity is expected to allow screening of thyroid dysfunctions in 
primary care. 
The performance of the TPX technique is independent of the assay 
volume and hence allows analysis from 1 µL reaction volumes. In such 
a volume, the 20 femtomolar detection limit amounts to 10 000 analyte 
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molecules. The method is one of the most sensitive assays reported in 
the literature in terms of the number of analyte molecules. It can be 
argued that the method approaches the theoretical lowest limit of 
detection of the current instrumentation; the detection limit 
corresponds to an analyte concentration of four antigen molecules per 
solid phase microsphere. In such low analyte concentrations, 
imprecision is expected to be tens of percents as individual 
microspheres which are bound from zero to four nanoparticles (via 
























Figure 1. Dose-response curves for hTSH methods applying molecular 
tracer (MT, dashed line zero + 3SD) and nanoparticulate tracer (NPT, 
dotted line zero + 3SD). Standard sample was diluted into the assay 
reaction by a factor of two. Incubation time was two hours. 
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Appendix 3: Concomitant assay method 
for influenza A and B viruses 
Introduction and Experimental 
The clinical manifestations of, and the empirical treatment for, 
influenza A and B virus infections are the same. Moreover, new 
antiviral drugs are effective in both infection types. Therefore, 
differentiation between the two (A or B) is of minor importance, both 
for the physician and for the patient. On this basis, it would be justified 
to combine the two assay methods in one more general influenza virus 
method, which would detect both virus types. 
To demonstrate this method option in the TPX platform, we prepared a 
combination reagent for influenza A and B viruses by coating 
microspheres with a 1:1 mixture of influenza virus antibodies against 
A (clone A3) and B (clone B2). These microspheres were used to 
capture influenza A and B virus nucleoprotein antigens from the 
samples. A mixture of fluorescently labelled antibodies (molecular for 
influenza A virus of clone A1, and nanoparticulate for influenza B 
virus of clone 2/3) was used as detection probe. Consequently, the 
method gives a signal response irrespective of the virus type. 
Results and Discussion 
The results of the concomitant assay method showed that at the 15-
minute incubation time point 19 out of 20 influenza A virus positive 
samples and 11 out of 16 influenza B virus positive samples were 
deemed positive (Figure 1a), while at 35 minutes, all 36 samples were 
tested positive (Figure 1b). All negative samples (N=20) were below 
the cut-off level. Figures 1a and 1b demonstrate how the detection 
rate (sensitivity) and the signals increase with incubation time. 
Pearson correlations for the concomitant assay signals versus reference 
TR-FIA method signals, and concomitant assay signals versus 
individual TPX method signals were 0.8 (p<0.0001) and 0.9 
(p<0.0001), respectively. Despite differences in the detection 
techniques and the methods, the signals obtained from the clinical 
samples with different methods correlated well, and each sample 
provided the same clinical result. 
When compared to the individual assay methods, the signal-to-
background ratios of the concomitant method for influenza A and B 
virus positive samples were lower by a factor of two (2) and three (3), 
Appendix 
 74
respectively. The absolute signal levels were, however, lower only by a 
factor of 1.3 for influenza A virus, and 1.7 for influenza B virus. The 
lower absolute signal levels can be explained by the lower capacity of 
the solid-phase per specific antibody, while lower signal-to-
background ratios are also contributed to by increased solution 
background fluorescence. In the concomitant assay, the solution 
background fluorescence was increased by a factor of approximately 
two because the assay reaction contained two different tracers, one for 
influenza A and one for influenza B viruses. The decrease in solid-
phase capacity could be compensated for by the use of high capacity 
streptavidin microspheres or similar approach. 
In conclusion, the performance of the concomitant method was 
somewhat compromised compared to individual methods. The results 
indicate, however, that the method still provided sufficient clinical 
sensitivity. Using this approach, measurement time per sample was cut 
to half (from 50 seconds to 25 seconds per sample per measurement 







































Figure 1. Figures demonstrating the performance of the concomitant TPX 
method for rapid detection of influenza A and B virus antigens (a) at the 15-
minute and (b) at the 35-minute time points of incubation. (+) samples 
positive for influenza A virus by TR-FIA, (×) samples positive for influenza 
B virus by TR-FIA. Dashed line represents the cut-off level of the method. 
All influenza negative samples (N=20) remained below the cut-off. 
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